ABOUT THE REPORT

Reporting Period

This Environmental, Social and Governance (ESG) Report (hereinafter referred as the "**Report**") covers the period from January 1 to December 31, 2024, with some content moderately extended forward and backward. The reporting period covered in the Report is consistent with that of our annual report.

Entity Scope

The entity scope covered in the Report is consistent with that of our annual report, including 3D Medicines Inc. and its subsidiaries.

Basis of Preparation

The Report is prepared in accordance with the provisions of Appendix 27 *Environmental, Social, and Governance Reporting Guide* (hereinafter referred to as the "**Guide**") to the *Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited* and a summary of its major amendments. The Report has been reviewed and approved by the Company's Board of Directors (the "**Board**"). Readers can refer to the last chapter of the Report – "Appendix: Index to the Environmental, Social and Governance Reporting Guide of The Stock Exchange of Hong Kong Limited" for quick reference.

Data Source

All the qualitative and quantitative information used in the Report originates from public information, internal documents, and relevant statistical data of 3D Medicines.

關於本報告

報告時間範圍

環境、社會及管治(「**ESG**」)報告(本「**報告**」)涵蓋的期間為2024年1月1日至2024年12月31日，部分內容向前後適度延伸。本報告涵蓋的時間範圍與我們的年度報告一致。

實體範圍

本報告涵蓋的實體範圍與我們的年度報告一致，包括思路迪醫藥及旗下子公司。

編製依據

本報告按照聯交所上市規則附錄二十七所載的《環境、社會及管治報告指引》(下稱「**指引**」)及其主要修訂概要編製而成。本報告經公司董事會(「**董事會**」)審閱並批准通過。讀者可參考本報告的最後一個章節－「附錄：香港聯交所《環境、社會及管治報告指引》內容索引」，以便快速查閱。

資料來源

本報告使用的定性及定量資料均來自思路迪醫藥的公開資料、內部檔案和相關統計數據。

Preparation Principle

The Report considers the importance, quantification, balance, and consistency of specific indicators related to performance disclosure on major ESG topics. Importance: Identify and rank important topics for stakeholders through policy and standard analysis and communication with stakeholders; Quantification: All key performance indicators ("**KPIs**") disclosed can be measured; Balance: Objectively present the Company's work in ESG in the Report; Consistency: The ESG report in this year adopts the same data disclosure method as previous years and compares data from different years, and lists changes in statistical methods and key performance indicators.

Reference Help

For ease of expression and reading, 3D Medicines Inc. is also referred to as "the Company" or "we" in the Report. Unless otherwise defined, the terms and definitions used in the Report have the same meaning as those used in the 2024 annual report.

Release Form

The electronic version of the Report is available at the HKEX website (www.hkex.com.hk) and the official website of 3D Medicines Inc. (https://www.3d-medicines.com/).

編製原則

本報告考慮了與主要ESG議題績效披露相關的各具體指標的重要性、量化性、平衡性以及一致性。重要性：通過政策及標準分析、利益相關方溝通，識別並排序對利益相關方而言重要的議題；量化性：披露的關鍵績效指標(「**關鍵績效指標**」)均可予以計量；平衡性：在報告中客觀地呈現了公司在ESG方面的工作；一致性：本年度的ESG報告採用了與以前年度一致的數據披露方法，並就不同年度的數據進行了比對，列示了統計方法和關鍵績效指標的變動。

指代說明

為方便表述和閱讀，「思路迪醫藥」在本報告中也以「3D Medicines」，「公司」或「我們」表示。除另有界定者外，本報告所用的辭彙及定義與2023年年報具有相同意義。

發佈形式

本報告網路版可在聯交所網站(www.hkex.com.hk)及思路迪醫藥網站(https://www.3d-medicines.com/)查閱下載。

MESSAGE FROM THE CHAIRMAN

With the increasing attention and further development of ESG principles, the company has integrated environmental, social, and governance initiatives into daily operations as a key focus in 2024. We remain committed to sustainable development, guided by our vision of "helping patients live longer and better lives." Centered on patient needs, we constantly explore superior treatment options while establishing a top-tier innovative pharmaceutical enterprise that is friendly to both the environment and society.

The company is dedicated to establishing a comprehensive ESG management system. The Board of Directors serves as the ultimate decision-making body for ESG matters, with the Board Office overseeing strategy implementation. An ESG Task Force has been formed to execute and deepen the practical application of ESG management.

Innovation and R&D remain the driving forces of our sustainable development. Focusing on the chronic disease management of cancer, we strive to provide patients with more effective, convenient therapies and improved treatment options earlier. This year, we achieved breakthroughs in cutting-edge research areas including mRNA cancer vaccines and radiopharmaceuticals. Our commercialized product 恩維達® received recommendations in four additional clinical treatment guidelines, gained inclusion in multiple regional healthcare insurance programs, and provided medication assistance through charitable donations and various channels, enhancing drug accessibility while reducing patient burdens.

Patient responsibility represents the most critical social obligation for pharmaceutical companies. We have further strengthened our Quality Management System to ensure systematic oversight of R&D, production, and sales processes across our operations and supply chain partners, effectively controlling product risks. Through multiple platforms and third-party suppliers, we actively gather patient feedback to provide medication guidance and ensure safe, proper drug usage.

Collaborative partnerships form a cornerstone of our development philosophy. In 2024, we established global full-industry-chain collaborations with leading domestic and international innovative pharmaceutical companies, spanning R&D, production, and commercialization. Notably, we signed a USD700 million overseas licensing agreement with multinational pharmaceutical distributor Glenmark to advance 恩維達®'s development and commercialization in emerging markets.

董事長致辭

隨著ESG理念關注度的提高及進一步發展，2024年公司將環境、社會和管理作為重要工作融入日常運營當中。我們始終秉持著可持續的發展理念，以「幫助患者活得更久更好」為願景，始終堅持以患者為中心，不斷探索更優治療選擇，堅持建設環境與社會友好型的一流創新藥企業。

公司致力於打造完善的ESG管理系統。ESG工作以董事會為最高決策機構，由董事會辦公室負責戰略實施和管理，並成立ESG工作小組負責ESG管理的具體事務執行和深化落實。

創新和研發始終是公司可持續發展的動力，我們重點聚焦於腫瘤慢病化領域，希望儘早地讓患者用上更有效、更便捷的腫瘤治療藥物，給病人提供更優的治療選擇。今年，我們繼續開展前沿腫瘤治療領域的研發，在mRNA腫瘤疫苗及核藥等領域取得了令人驚喜的突破。同時，我們的商業化產品恩維達®今年再次獲得4項臨床治療指南推薦，進入多地惠民保，通過慈善捐贈及多種渠道，提供藥品援助，在提高藥物可及性的同時，減少患者的負擔。

對患者負責是醫藥公司最重要的社會責任，因此我們繼續完善質量管理系統，讓我們以及上下游企業的研發、生產、銷售可以受到系統化的監督與管理，控制產品風險。同時，我們通過各平台以及第三方供應商，及時瞭解患者訴求，為患者提供用藥指導，保證患者正確安全地使用我們的藥品。

合作共贏是公司重要的發展理念。2024年，我們已與多家國內外領先的創新藥企業及跨國醫藥企業合作，在全球範圍內開展從研發、生產最終到銷售的全產業鏈合作模式。2024年，我們與國際大型藥品銷售企業Glenmark簽署超過7億美元的海外授權協議，全面開展恩維達®在新興市場的開發與商業化計劃。

Employees constitute the foundation of corporate creativity and growth. We maintain people-oriented policies through fair and transparent recruitment, employment, and career development mechanisms. The company provides comfortable working environments, regular health checkups, and commercial medical insurance. We proactively support employee health and safety through fitness initiatives, fire drills, and emergency evacuation training. To recognize staff contributions, we hosted an annual summit in early 2024 featuring outstanding employee awards, team-building activities, and exploration trips designed to boost morale and collaboration. Regional branches organized cultural and sports events including Beijing relay marathons, Shanghai food festivals, and Guangzhou tug-of-war competitions, fostering learning cultures through reading clubs and recognition programs.

員工是企業創造力和發展的基石。公司持續以人為本，建立公平透明的人員僱傭，甄選，發展機制，為員工提供舒適健康的工作環境，提供定期體檢和商業醫療保險。我們倡導運動健身，在員工的健康與安全方面提供主動的支持。我們為表彰員工一年的辛苦付出，在2024年初舉辦年度總結大會，表彰優秀員工，開展素質拓展和旅行探索活動，我們相信在活動中，可以有效提振公司整體士氣，促進員工溝通交流，提高工作效率。我們加強防火及逃生演習，保證員工在突發事件時，有明確的應對方案。同時，我們繼續倡導團隊文化建設，各地分公司積極組織建設及體育活動，如在北京開展接力馬拉松活動，在上海舉行美食節比賽等，在廣州舉辦拔河比賽等。營造員工積極學習的氛圍，通過讀書評獎，鼓勵員工積極向上。

We uphold ethical operations through enhanced risk and internal control management. Anti-corruption initiatives and dedicated compliance supervision departments have been established. Procurement processes have been optimized with transparent management systems, tripartite price comparisons, and market-oriented purchasing practices.

公司持續誠信經營，不斷加強風險與內控管理。我們在內部推行反貪淨化工作，並設立專門的監督管理部門。同時，我們逐步優化公司採購制度，開展採購的透明化管理，實施三方比價，宣導市場化採購與合作。

Our green environmental management system minimizes ecological impacts from R&D and production operations. Advanced wastewater treatment and exhaust emission systems ensure safe discharge management, complemented by waste liquid recycling programs that conserve resources and reduce costs. We actively address climate change by identifying related opportunities and challenges, implementing energy conservation measures to build an eco-friendly society.

我們建立綠色的環境管理系統，在實驗生產的同時，減少對環境的影響與危害，加強對廢液的回收，節省資源以及成本。我們使用先進的污水處理系統和廢氣排風系統以保證有害物質的安全排放。我們積極應對氣候變化，甄別與評估氣候變化可能帶來的機遇與挑戰，盡可能地減少能源使用與消耗，建立環境友好型社會。

Moving forward, we will continue pursuing our overarching ESG goal of building an environmentally and socially responsible sustainable enterprise. By balancing stakeholder interests, focusing on key priorities, strengthening ESG oversight and target-setting, and conducting regular reviews, we will systematically plan, implement, monitor, and refine ESG management across all operational dimensions.

未來，我們將繼續以打造環境社會友好型可持續發展企業為總體ESG戰略目標，考慮全部利益相關人的共同利益，依據公司重要議題，加強ESG監管和目標設定，並定期回顧，從各個角度計劃、實施、監督、完善公司ESG管理。

COMPANY PROFILE

3D Medicines Inc. ("**3D Medicines**", Stock Code: 1244.HK) is a foreign-invested private innovative pharmaceutical company in the commercialization phase, dedicated to the chronic disease management of cancer treatments. Guided by its vision of "Help people with cancer live longer and better", the company focuses on developing next-generation anti-tumor therapies and was successfully listed on the Hong Kong Stock Exchange Main Board in 2022. As the first listed company specializing in cancer treatment chronic disease management on HKEX, it once achieved a market capitalization exceeding HK$34 billion. The company's pipeline comprises 12 innovative drugs with differentiated clinical value or global-leading potential, including 8 candidates in clinical development or commercialization stages. Notably, 恩維達® – the world's first subcutaneously administered PD-L1 single-domain antibody – has been approved by China's NMPA for three years, generating over RMB2 billion in sales revenue. This breakthrough therapy has brought new hope and improved quality of life for tens of thousands of Chinese cancer patients and their families. 3D Medicines maintains forward-looking positioning in global-leading research programs including antibody immunotherapy, mRNA cancer vaccines, and radio-pharmaceuticals. Leveraging its proprietary mRNA R&D platform, internationally patented LNP technology, and AI-driven tumor genomic big data analytics platform, the company is developing a series of mRNA products. Its first pan-cancer vaccine is scheduled for dual China-U.S. regulatory submissions this year. Concurrently, its in-house developed radio-pharmaceuticals are advancing to the pre-clinical stage. The company has established full-cycle capabilities spanning from drug discovery, pre-clinical research, clinical development, to regulatory approval and commercialization. Three subsidiaries have been recognized as National High-Tech Enterprises. In 2024, 3D Medicines was honored with the "ESG Social Responsibility Pioneer Enterprise Award" by CLS. Committed to patient-centric innovation, 3D Medicines continues to develop differentiated therapeutics with significant clinical value.

Vision: Help people with cancer live longer and better
Positioning: Leader in helping chronic tumor patients
Mission: Prolong the life span of cancer patients and improve the quality of their life

公司介紹

思路迪医药股份有限公司(思路迪醫藥股份,1244.HK)是一家進入商業化階段專注腫瘤慢病化治療領域的外資民營創新藥公司,秉承「幫助腫瘤患者活得更久更好」的願景,研發新一代抗腫瘤藥物,2022年公司登錄港交所主板。公司在香港聯交所主板成為腫瘤治療慢病化第一股,市值一度超過340億港幣。公司產品線包括12款具有差異化臨床價值或全球領先的創新藥,其中8款已進入臨床開發或商業化階段,包括全球首個皮下注射PD-L1單域抗體新藥恩維達®已獲國家藥品監督管理局批准上市三年銷售超過20億人民幣,為數萬中國腫瘤患者及家庭帶來新的希望,提高生活品質。公司前瞻性佈局全球領先的抗體免疫治療、mRNA腫瘤疫苗、抗腫瘤核藥等新藥研究項目,依託公司自有mRNA研發平台,國際專利LNP和腫瘤基因組大數據AI分析平台,研發一系列mRNA產品,其中第一款通用型腫瘤疫苗將在今年進行中美雙報。公司自主開發的創新型核藥產品,進入臨床前階段。公司建立了完整的藥物開發體系,涵蓋從藥物發現、臨床前研究、臨床開發、申報上市及商業化能力的全流程。公司有三個子公司屬於國家級高新技術企業,2024年獲得財聯社評定「ESG社會責任先鋒企業獎」。思路迪醫藥堅持以患者為中心,開發具有差異化臨床價值的創新藥。

願景:幫助腫瘤患者活得更久更好
定位:腫瘤慢病化治療市場的領導者
使命:延長腫瘤患者的生存時間,改善患者生活品質

1. R&D platform

The Company has a professional R&D platform in the field of managing tumor as a chronic disease, on which we can carry out a series of R&D activities including drug activity screening, drug cell function study, drug biochemical study and biomolecule detection.

The Company's R&D platform has strong molecular screening and design capabilities to increase the success rate of molecules from preclinical study to market, and support the R&D of pipeline assets built around key pathways and targets.

We have established mature R&D centers in Shanghai and Beijing respectively, including large and small molecular platforms, cell line screening platforms, and compound screening platforms.Based on the needs of our innovative R&D initiatives, we have newly established a synthesis and screening platform for ionizable cationic lipids – the key component in lipid nanoparticles (LNP) – to support the development of our nucleic acid drug pipeline.

We have established our own mRNA R&D platform and oncogenome big data AI analysis platform, With the powerful functions of these two platforms, a series of mRNA products are developed.

2. Product pipeline

We have established a diversified pipeline layout including 13 products and candidate drugs. Among them, Envafolimab Injection was approved for commercialization in China in November 2021. Currently, multiple pivitol Phase III clinical studies are underway, including those for non-small cell lung cancer, cholangiocarcinoma and so on.

Relying on our in-house mRNA research and development platform, tumor genome big data AI analysis platform, as well as our independently developed efficient and safe lipid delivery system, we have successfully developed a series of mRNA candidate drugs. The first non-personalized mRNA therapeutic cancer vaccine is about to file for an Investigational New Drug (IND) application this year.

1、 研發平台

我們擁有在腫瘤慢病化治療領域的專業研發平台，使我們可以進行包括藥物活性篩選、藥物細胞功能研究、藥物生化研究及生物分子檢測等的一系列研發活動。

我們的研發平台擁有強大的分子篩選和設計能力，可提高分子從臨床前研究推進至上市的成功幾率，可支持圍繞關鍵通路及靶點構建的管線資產研發。

在上海和北京分別建立技術成熟的研發中心，其中包括大小分子平台、細胞系篩選平台、化合物篩選平台。基於我們研發創新的需求，我們新建立了納米脂質微球(LNP)中關鍵組分－可電離陽離子脂質的合成和篩選平台，用於支持我們核酸藥物管線的開發。

公司自主搭建了mRNA研發平台和腫瘤基因組大數據AI分析平台，借助這兩大技術平台的強大功能，研發系列mRNA產品。

2、 管線情況

我們已建立包含13個產品及候選藥物的多樣化管線布局。其中，恩維達®(Envafolimab，恩沃利單抗注射液)，已於2021年11月在中國獲批並開展商業化，目前多個關鍵III期臨床研究正在推進，包括非小細胞肺癌、膽道癌等。

依託公司自有mRNA研發平台和腫瘤基因組大數據AI分析平台，以及自主研發的高效、安全的脂質遞送系統，我們成功開發了系列mRNA候選藥物，首款非個性化mRNA治療性腫瘤疫苗即將申報IND。

We also possess radiolabeled conjugate drugs at the pre-clinical stage. Preliminary pre-clinical data indicate their potential superiority over currently marketed similar products. Moreover, our pipeline encompasses diverse small-molecule targeted drugs, single/bispecific antibodies, immune checkpoint inhibitors, and peptide vaccines, spanning multiple stages of cancer treatment, from early to late.

我們亦擁有臨床前階段的放射性核素偶聯藥物，初步臨床前數據顯示出相比已上市同類產品具有優效潛力。此外，管線中還包含多種小分子靶向藥物、單／雙特異性抗體、免疫檢查點抑制劑及多肽疫苗等，覆蓋了從早期到晚期腫瘤治療的多個階段。

We are dedicated to developing innovative drugs, aiming to address unmet clinical needs and offer more hope and choices to cancer patients.

我們致力於通過創新的差異化的藥物開發，以覆蓋未被滿足的臨床需求，為癌症患者帶來更多的希望和選擇。

Candidate 候選藥物	Target/Mechanism 靶點／機制	Indications/Study Population	適應症／研究人群	Rights 權利	Pre-clinical Discovery 臨床前發現	IND	Phase I I期	Phase II II 期	Phase III III 期	NDA
Envafolimab 恩沃利單抗	PD-L1	MSI-H/dMMR Advanced Cancer (Mono, 2L+)	MSI-H/dMMR晚期實體瘤（單藥，2L+）	Global 全球	Greater China 大中華區					BLA Approved 獲批上市
		Advanced BTC (Combo with chemo vs. chemo, 1L)	晚期膽道癌（與化療聯用vs化療，1L）		China 中國					
		NSCLC (Adjuvant/Neo-adjuvant therapy, 1L)	非小細胞肺癌（輔助／新輔助治療，1L）		China 中國					
		G/GEJ Advanced Cancer (Combo with chemo, 1L)	晚期胃癌及胃食管交界處癌（與化療藥聯用，1L）		China 中國					
		TMB-H Advanced Cancer (Mono, 2L+)	TMB-H晚期癌症（單藥，2L+）		China 中國					
		EC (Mono and combo with lenvatinib, 2L+)	子宮內膜癌（單藥，與lenvatinib聯用，2L+）		China 中國					
		HCC, CRC, NSCLC (Combo with BD0801)	肝癌、結直腸癌、非小細胞肺癌（與BD0801聯用）		China 中國					
		Microsatellite Stable CRC (Combo with cetuximab+/-Fruquintinib, standard treatment failure)	微衛星穩定CRC（與cetuximab聯用+/-Fruquintinib，經標準治療失敗）		China 中國					
		dMMR Advanced Solid Tumor (Mono, 2L+)	dMMR晚期實體瘤（單藥，2L+）		Global 全球					
3D189	WT1 CancerVaccine WT1腫瘤疫苗	Multiple Indications	多適應症	Greater China 大中華區	China 中國					
		AML	AML		Sellas					
3D229	GAS6/AXL	Healthy Volunteers	健康志願者	Greater China 大中華區	China 中國					
3D1001	COX-2	Post-surgical Dental Pain/Cancer Pain	術後牙痛／癌痛	Greater China 大中華區	China 中國 USA 美國					
3D1002	EP-4	Primary dysmenorrhea/Osteoarthritis	原發性痛經／骨關節炎	Greater China 大中華區	China 中國 USA 美國					
3D185	FGFR1/2/3	Locally Advanced or Metastatic Solid Tumors	局部晚期或轉移性實體瘤	Global 全球	China/USA 中國／美國					
3D011	TKI prodrug TKI 前藥	Advanced Malignant Solid Tumors	晚期惡性實體瘤	Global 全球	China 中國					
3D1015	RDC	mCRPC	轉移性去勢抵抗性前列腺癌	Global 全球						
3D124	mRNA Cancer Vaccine mRNA腫瘤疫苗	Multiple Indications	多適應症	Global 全球						
3D197	CD47	Multiple Indications	多適應症	Greater China 大中華區	China 中國					
3D057	CD3+PD-L1	Multiple Indications	多適應症	Greater China priority transfer rights 大中華區 全球優先受讓權						
3D062	KRAS	Multiple Indications	多適應症	Global 全球						
3D059	WT1 Cancer Vaccine WT1腫瘤疫苗	Multiple Indications	多適應症	Greater China 大中華區						

Pivotal Trial 註冊性臨床

3. Major Events in 2024

January

In January, 2024, 3D Medicines and Jiangsu Alphamab (the "**Licensors**"), and Glenmark (the "**Licensee**") entered into a license agreement (the "**License Agreement**"), pursuant to which, the Licensors agreed to grant the Licensee an exclusive license and the right to sublicence in respect of oncology indications of Envafolimab, among others, (a) develop Envafolimab in India, Asia Pacific (except Singapore, Thailand and Malaysia), Middle-east and Africa, Russia, the Commonwealth of Independent States and Latin America (the "**Territory**") for the purpose of commercialization in all field of use in oncology (the "**Field**") in the Territory; and (b) commercialize Envafolimab in the Field in the Territory, subject to the terms and conditions of the License Agreement. The Licensee will develop and commercialize Envafolimab in the Field in the Territory at its own cost and expense.

恩維達® was registered and listed with the Macau Pharmaceutical Administration. In January 2024, 恩維達® was successfully registered and listed with the Macau Pharmaceutical Administration Bureau for the treatment of adult patients with advanced solid tumors that are unresectable or metastatic with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR).

3、 2024年大事記

1月

2024年1月，思路迪醫藥及江蘇康寧傑瑞(「**許可人**」)與Glenmark(「**被許可人**」)訂立許可協議(「**許可協議**」)，據此，許可人同意向被許可人授予恩沃利單抗腫瘤適應症的獨家許可及再授權，以(其中包括)(a)在印度、亞太區(新加坡、泰國及馬來西亞除外)、中東及非洲、俄羅斯、獨立國家聯合體及拉丁美洲(「**地區**」)開發恩沃利單抗，以在該地區實現腫瘤所有使用領域(「**領域**」)的商業化；及(b)在地區內有關領域商業化恩沃利單抗，惟須遵守許可協議的條款及條件。被許可人將自行承擔在地區內於該領域開發及商業化恩沃利單抗的有關費用及開支。

恩維達®於澳門藥物監督管理局註冊登記並上市。2024年1月，恩維達® 成功於澳門藥物監督管理局註冊登記並上市，用於不可切除或轉移性微衛星高度不穩定(MSI-H)或錯配修復基因缺陷型(dMMR)的成人晚期實體瘤患者的治療。

On January 26, 2024, the signing ceremony of the strategic cooperation between the Company and Qingdao Sino Cell Biomedicine Co, Ltd. ("**Sino-Cell Biomed**") was held in Shanghai, China. Dr. Gong Zhaolong, Chairman of the Board and CEO of the Company, and Mr. Gao Qing, Chairman of the Board of Directors of Sino-Cell Biomed, entered into the strategic cooperation agreement. The agreement aims to facilitate joint research efforts in innovative therapy within the field of oncology immunotherapy, leveraging the respective advantages of both parties. The agreement aims to jointly research innovative therapies in the field of tumor immunotherapy based on their respective advantages, explore new cooperation models, and provide better treatment options for cancer patient

2024年1月26日，本公司與青島華賽伯曼醫學細胞生物有限公司(簡稱「**華賽伯曼**」)戰略合作的簽約儀式在中國上海舉行。本公司董事長兼首席執行官龔兆龍博士和華賽伯曼董事長高青先生簽署了戰略合作協議。該協議旨在雙方依託各自優勢共同研究腫瘤免疫治療領域創新療法，探索新型合作模式，為腫瘤患者提供更好治療的選擇。

February

On February 21, 2024, 3D Medicines Inc. and Novatim strategic cooperation signing ceremony was held in Shanghai, which aims to explore the combination of 恩維達® (Envafolimab) and KY-0118. In addition, the two parties will also discuss further cooperation in many aspects such as the product rights and interests of Novatim Pharmaceutical's double•target CAR-T and global clinical trial research.

March

In March 2024, Professor Kuang Ming from the First Affiliated Hospital of Sun Yat-sen University presented at the 33rd Annual Meeting of the Asia-Pacific Association for the Study of the Liver (APASL). He reported on the clinical study of PD-L1 inhibitors combined with chemotherapy and targeted therapy (envafolimab and durvalumab) in 43 patients with advanced biliary tract cancer. The study showed a median progression-free survival of 11.29 months and a median overall survival of 14.8 months.

April

The ongoing Phase III overseas clinical study of 3D189 for the treatment of acute myeloid leukemia (AML), led by our partner SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), underwent positive reviews by the Independent Data Monitoring Committee (IDMC) on April 29, 2024, and June 17, 2024. Following two times reviews, the IDMC conducted a prespecified risk-benefit assessment of unblinded data from the study and has recommended that the trial continue without modifications. Based on a detailed analysis of all unblinded data, the IDMC projects with a high level of confidence that the interim analysis (60 events) will occur by the fourth quarter of 2024. On January 23, 2025 as receiving a positive outcome from the Independent Data Monitoring Committee (IDMC). Following an interim analysis triggered by 60 events (death) in the study population, the IDMC conducted a predetermined benefit/risk assessment of the unblinded data from the study and recommended that the trial continue without modification. SELLAS anticipates that next and final analysis (80 events) will be reached this year.

2月

2024年2月21日，與科弈戰略合作簽約儀式在上海舉行。本次合作旨在對恩維達®(恩沃利單抗)與KY-0118藥物聯用展開探索。此外，雙方還將在科弈藥業雙靶點CAR-T的產品權益、全球臨床試驗研究等多方面探討進一步合作

3月

2024年3月，中山大學附屬第一醫院匡銘教授出席亞太肝病研究學會(APASL)第33屆年會，口頭報告了PD-L1抑制劑聯合化療與靶向治療(恩沃利單抗和度伐利尤單抗)在43例晚期膽道癌患者中的臨床研究。該研究顯示中位無進展生存期為11.29個月，中位總生存期為14.8個月。

4月

我們的合作夥伴SELLAS Life Sciences Group, Inc.(納斯達克：SLS)領導的3D189治療急性髓性白血病(AML)的正在進行的III期海外臨床研究於2024年4月29日及2024年6月17日獲得獨立資料監察委員會(IDMC)的積極評價。於兩次審查完成後，IDMC已對研究的非盲數據進行預定獲益／風險評估，並建議繼續進行試驗而不進行修改。根據對所有非盲數據的詳細分析，IDMC堅信中期分析(60個事件)於2024年第四季度進行。於2025年1月23日宣佈獲得獨立數據監察委員會(IDMC)的積極評價。在由研究人群中的60個事件(死亡)觸發的中期分析之後，IDMC對研究的非盲數據進行預定獲益／風險評估，並建議繼續進行試驗而不進行修改。SELLAS預計下一次也是最終分析(80個事件)將在今年觸發。

May

In May 2024, at the American Society of Clinical Oncology (ASCO) Annual Meeting, nine studies on envafolimab were selected for presentation, including four poster presentations and five online publications. The research covered areas such as biliary tract cancer, liver cancer, rectal cancer, endometrial cancer, esophageal squamous cell carcinoma, and gastric/gastroesophageal junction adenocarcinoma.

Among these, the first clinical data of envafolimab combined with lenvatinib for the treatment of advanced endometrial cancer that has failed at least one line of platinum containing chemotherapy or is intolerant to it, and is non-MSI-H/non-dMMR, was disclosed in a poster presentation. This study had previously been included as a breakthrough therapy by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA). Currently, there is no standard treatment for this indication in China. The available chemotherapy drugs, PD-1/PD-L1 inhibitors, and lenvatinib monotherapy for endometrial cancer have shown low objective response rates and survival indicators. The disclosure of this data suggests that envafolimab combined with lenvatinib may provide a more effective, safer, and more convenient new clinical treatment option for patients with advanced endometrial cancer who have failed at least one line of platinum-containing chemotherapy or are intolerant to it.

Another noteworthy study is the ENLIGHTEN Study. This is a single-arm, open-label, phase II study aiming to investigate the efficacy and safety of Envafolimab, combined with Lenvatinib and gemcitabine plus cisplatin in patients with advanced biliary tract cancer (BTC). Based on the interim analysis, the ORR and DCR were 45% and 80% respectively. Survival data is expected.

5月

2024年5月，九項關於恩沃利單抗的研究獲選在美國臨床腫瘤學會(ASCO)年會展示，其中四項為壁報展示，五項為線上刊物。該項研究涵蓋膽道癌、肝癌、直腸癌、子宮內膜癌、食管鱗狀細胞癌及胃／食管胃結合部腺癌等領域。

其中，恩沃利單抗聯合樂伐替尼用於治療既往至少一線含鉑化療失敗或不能耐受的非MSI-H／非dMMR晚期子宮內膜癌的臨床數據，通過壁報展示形式披露。該研究先前已獲中國國家藥品監督管理局(國家藥監局)藥品審評中心(CDE)納入突破性治療藥物。目前，在中國沒有針對這一適應症的獲批標準治療。可用於治療子宮內膜癌的化療藥物、PD-1/PD-L1抑制劑及樂伐替尼單藥療法的客觀緩解率及生存指標均較低。披露的該數據表明，恩沃利單抗聯合樂伐替尼可為既往至少一線含鉑化療失敗或不能耐受的晚期子宮內膜癌患者提供更為有效、安全且便利的新臨床治療選擇。

另一項值得注意的研究是ENLIGHTEN研究。這是一項單臂、開放標籤、II期研究，旨在探索恩維達®聯合侖伐替尼和吉西他濱聯合順鉑在晚期膽道腫瘤(BTC)患者中的療效和安全性。從初步分析來看，ORR和DCR分一別為45%和80%。生存數據未來將公佈。

July

In July, 2024, the Company received a notification of approval for a Supplemental New Drug Application (sNDA) for 恩維達® (Envafolimab injection) from the National Medical Products Administration. The approval included the change of self developed media and adding new raw material suppliers, the internal control standards for some new raw materials and the change of production scale from 1,000L to 2,000L etc. The supplemental application was supported by the data from a randomized, double-blind, single-dose, parallel controlled Phase I clinical study to evaluate the Pharmacokinetics, safety, and immunogenicity of Envafolimab Injection in healthy male subjects (ClinicalTrials.gov, NCT05849311), which demonstrated that 恩維達® has stable manufacturing process and sufficient clinical data. The expansion of production capacity can fully meet the market demand.

August

In August 2024, 恩維達® was granted Breakthrough Therapy Designation (BTD) by the NMPA for the treatment of patients with unresectable or metastatic tumor mutational burden-high (TMB-H) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. This indication addresses life-threatening conditions for which there are currently no approved standard therapies in China. In recent years, high tumor mutational burden (TMB) has been utilized in the United States as a biomarker for tissue agnostic drug development by the FDA.

September

In September 2024, 恩維達® presented clinical data from a Phase II study (NCT05243355) evaluating the combination of recombinant human endostatin and chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC) in a poster format. Among the 24 efficacy evaluable subjects, the ORR was 81% and the DCR was 100%, with no new safety signal. This finding demonstrated the combination of Envafolimab plus angiogenesis inhibitor and chemotherapy resulted in a favorable clinical efficacy with tolerable safety profile in advanced sq-NSCLC, representing a promising treatment regimen for this population.

7月

2024年7月，本公司收到國家藥品監督管理局簽發的恩維達®（恩沃利單抗注射液）補充新藥申請(sNDA)批准通知書。批准變更為自主開發培養基，新增各部分原材料供應商，新增部分原材料的內控標準以及生產規模由1000L變為2000L等事項。此次補充申請獲批基於一項「評估恩沃利單抗注射液在健康男性受試者中的藥代動力學、安全性和免疫原性的隨機、雙盲、單劑量、平行對照I期臨床研究」(ClinicalT rials.gov，NCT05849311)的試驗數據，表明恩維達®工藝穩定，臨床研究充分，具備擴大生產能力，充分滿足市場需求。

8月

2024年8月，恩維達®已被批准作為治療既往標準治療失敗且沒有令人滿意的替代療法的高腫瘤突變負荷(TMB-H)不可切除或轉移性實體瘤患者的一種突破性療法。該適應症涉及危及生命的疾病，目前在中國尚無批准的標準治療方法。近年來，高腫瘤突變負荷(TMB)已在美國被用作FDA批准的「泛瘤種」新藥項目的生物標誌物。

9月

2024年9月，恩維達®（恩沃利單抗注射液）於世界肺癌大會(WCLC)以壁報形式展示一項關於聯合重組人血管內皮抑素和化療在晚期鱗狀非小細胞肺癌(sq-NSCLC)一線治療的II期研究(NCT05243355)臨床數據，該研究，是一項單臂、多中心、前瞻性II期研究，評估了恩維達®聯合重組人血管內皮抑素(Re-endostatin)和化療在晚期鱗狀非小細胞肺癌(sq-NSCLC)一線治療中的療效和安全性，數據顯示，客觀緩解率(ORR)為81%，疾病控制率(DCR)達100%。雖然生存數據尚未成熟，但初步結果表明，該聯合療法在晚期sq-NSCLC患者中療效顯著，且安全性方面表現良好。

Meanwhile, a team led by Professor Di Ge from Zhongshan Hospital, Fudan University, also presented a prospective study outcome titled "Efficacy and Safety of Envafolimab Plus Platinum based Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB NSCLC" at the World Conference on Lung Cancer (WCLC). The study aimed to evaluate the efficacy and safety of envafolimab combined with platinum based chemotherapy as neoadjuvant therapy in patients with resectable stage II-IIIB NSCLC. Thirteen patients were enrolled. The pCR rate was 30.7%, and the MPR rate was 53.8%. R0 resection rate reached 92.3%. Only two patients (15.4%) experienced grade 3 or 4 treatment-related adverse event. No grade 5 TEAE related to Envafolimab were reported. Results indicated that the combination elicited favorable safety profiles and promising a novel option for neoadjuvant treatment.

同時，復旦大學附屬中山醫院的葛棣教授團隊於世界肺癌大會(WCLC)亦展示了一項題為「Efficacy and Safety of Envafolimab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB NSCLC」的重要研究，旨在探索恩沃利單抗聯合含鉑化療術前新輔助治療在II-IIIB期NSCLC患者中的療效和安全性，研究共納入13例患者。病理完全緩解(pCR)率為30.7%，主要病理緩解(MPR)率為53.8%，R0切除率達92.3%。僅2例患者(15.4%)報告了至少1例3級或4級治療相關不良事件，未發生與恩沃利單抗相關的5級治療相關不良事件。研究結果表明，恩沃利單抗聯合含鉑化療在II-IIIB期可切除NSCLC患者中展現出良好的安全性和病理完全緩解率，為新輔助治療提供新的選擇。

In September 2024, Professor Wei Li from the First Affiliated Hospital of Soochow University presented interim data from the B-Enefit study (ChiCTR2400080783), a Phase II trial evaluating 恩維達® (envafolimab injection) in combination with GEMOX chemotherapy and chidamide as first-line treatment for advanced biliary tract cancer (BTC) at the ESMO Congress. The study enrolled advanced BTC patients with no prior systemic anti-tumor therapy. Preliminary results showed that among 22 evaluable patients (16 with cholangiocarcinoma and 6 with gallbladder cancer), the ORR and DCR reached 50% and 77.27%, respectively, while median progression-free survival (PFS) and overall survival (OS) were not yet reached. The incidence of grade 3 or higher treatment-related adverse events (TRAEs) was 59.9%, with no treatment-related deaths reported. These results suggest that the combination of 恩維達®, chidamide, and chemotherapy exhibits promising antitumor activity with a manageable safety profile.

2024年9月，蘇州大學第一附屬醫院李偉教授於2024歐洲腫瘤內科學會(ESMO)發表恩維達®(恩沃利單抗注射液，ENWEIDA®)一項在一線晚期膽道癌(BTC)患者中的II期研究(ChiCTR2400080783)B-Enefit的中期數據，該試驗為一項評估恩維達®和西達本胺聯合GEMOX針對未經系統治療的晚期BTC患者的II期臨床研究。初步結果顯示，在22例(16例膽管癌和6例膽囊癌)可評估患者中，50%的患者達到部分或完全緩解，77.27%患者實現了疾病控制。中位隨訪8.5個月，中位PFS和OS均未達到。最常見的治療相關不良事件(TRAE)為貧血(54.55%)、血小板計數減少(59.09%)和白細胞減少(45.45%)。3級及以上的TRAE發生率為59.9%，無治療相關死亡病例發生。意味着恩維達®聯合西達本胺和化療的療法具有良好的抗腫瘤活性，且安全性可控。

In September 2024, the PRECAM study led by Professor Sheng Dai's team at Sir Run Run Shaw Hospital of Zhejiang University was published in the high-impact journal *International Journal of Surgery* (IF 12.5). The study focused on MSS-type locally advanced rectal cancer and aimed to evaluate the efficacy of a neoadjuvant regimen combining short-course radiotherapy followed by envafolimab and CAPEOX. Preliminary results showed that short-course chemoradiotherapy combined with envafolimab achieved a remarkable pathological complete response (pCR) rate of 62.5% in MSS locally advanced rectal cancer patients – 20 out of 32 patients completed surgery reached pCR. This suggests that neoadjuvant short-course chemoradiotherapy combined with immunotherapy can lead to higher pCR rates for MSS locally advanced rectal cancer, thereby improving organ preservation rates and enhancing patients' quality of life. High organ preservation rates and quality of life are key goals in the treatment of locally advanced or low-lying rectal cancer.

October

In October 2024, a research team from the First Affiliated Hospital of Zhejiang University School of Medicine published a study titled "Envafolimab plus lenvatinib and transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC): a prospective, single-arm, phase II study" in Signal Transduction and Targeted Therapy. The study (NCT05213221) evaluated the efficacy and safety of TACE followed by envafolimab and lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC). Results showed that among 36 efficacy-evaluable patients, the objective response rate (ORR) and disease control rate (DCR) reached 50% and 83.3%, respectively. Notably, 17 patients achieved surgical conversion, with 16 completing surgery and an R0 resection rate of 100%. These findings suggest Envafolimab plus lenvatinib and TACE yielded promising survival outcomes and conversion efficiency with a tolerable safety profile.

2024年9月，浙江大學邵逸夫醫院戴勝教授團隊開展了針對MSS型局部晚期直腸癌的PRECAM研究，並發表於國際權威期刊《International journal of surgery》(IF 12.5)雜誌，旨在明確短程放療序貫恩沃利單抗聯合CAPEOX的新輔助治療方案的療效。研究初步結果顯示，短程放化療聯合恩沃利單抗給MSS局部晚期直腸癌患者帶來了高達62.5%的pCR，即32例入組的患者中，有20例患者達到了pCR。這意味着，對於MSS局部晚期直腸癌可以通過新輔助短程放化療聯合免疫治療達到更高的pCR，以實現更高的器官保留率，從而獲得更高的生活質量。高器官保留率和高生活質量是局部晚期直腸癌，或者説低位直腸癌治療努力的方向。

10月

2024年10月，浙江大學醫學院附屬第一醫院研究團隊在《Signal Transduction and Targeted Therapy》期刊發表了題為「Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study」的研究論文，該研究(NCT05213221)探討了TACE序貫恩沃利單抗和侖伐替尼在不可切除肝細胞癌(uHCC)患者中的療效與安全性。結果顯示，在36例療效可評估患者中，客觀緩解率(ORR)和疾病控制率(DCR)分別達到50%和83.3%。值得注意的是，17例患者轉化為可手術HCC，其中16例完成手術且R0切除率達100%。研究結果表明，TACE序貫恩沃利單抗和侖伐替尼具有良好的療效和安全性，且具有較高的手術轉化率和病理完全緩解率(pCR)，有望為中晚期uHCC患者帶來更大的臨床獲益。

December

December, 2024, the European Society for Medical Oncology Asia Congress (ESMO Asia) was held in Singapore. During the conference, results from a Phase II clinical trial led by Professor Qingming Shi from Anhui Chest Hospital were presented in a poster session. The findings suggested that for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), particularly for those patients had not received PD-L1 inhibitors in first-line treatment, envafolimab combined with chemotherapy or anti-angiogenic therapy may serve as an effective, safe, and convenient second-line treatment option.

In 2024, envafolimab was included in the 2024 edition of the "Chinese Expert Consensus on the Perioperative Treatment of Advanced Gastric Cancer with Immune Checkpoint Inhibitors" published by the Gastric Cancer Professional Committee of the Chinese Anti-Cancer Association and and the Expert Consensus on Pharmaceutical Services for the Clinical Application of Innovative Subcutaneous Formulations of Antitumor Drugs has been released by the Hospital Pharmacy Committee of the Chinese Pharmaceutical Association. With this inclusion, 恩維達® has now been recommended in 19 of the latest authoritative clinical guidelines and consensus recommendations both domestically and internationally.

① Chinese Edition of the "2023 NCCN Cervical Cancer Clinical Practice Guidelines (1st Edition)"

② Chinese Edition of the "2023 NCCN Uterine Tumor Clinical Practice Guidelines (2nd Edition)"

③ Chinese Edition of the "2023 NCCN Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer Clinical Practice Guidelines (2nd Edition)"

④ Chinese Expert Consensus on the Perioperative Treatment of Advanced Gastric Cancer with Immune Checkpoint Inhibitors (2024 Edition)

12月

2024年12月，歐洲腫瘤內科學會亞洲年會(ESMO Asia)在新加坡舉辦。本次ESMO Asia大會中，由安徽省胸科醫院史清明教授領銜的一項II期臨床試驗結果以壁報的形式公布。其結果顯示，對於局部晚期或轉移性非小細胞肺癌(NSCLC)患者，尤其是接受過PD-1抑制劑治療的患者，恩沃利單抗聯合化療或抗血管生成治療可能是一種有效、安全和方便的二線治療選擇。

2024年全年，恩沃利單抗被納入中國抗癌協會胃癌專業委員會發佈的2024版《免疫檢查點抑制劑用於進展期胃癌圍手術期治療的中國專家共識》以及中國藥學會醫院藥學專業委員會發佈的《抗腫瘤藥物創新皮下製劑臨床應用的藥事服務專家共識》。至此，恩維達®已進入19項中外權威臨床指南與共識推薦。

① 《2023 NCCN子宮頸癌臨床實踐指南（第1版）》（中文版）

② 《2023 NCCN子宮腫瘤臨床實踐指南（第2版）》（中文版）

③ 《2023 NCCN卵巢癌包括輸卵管癌及原發性腹膜癌臨床實踐指南（第2版）》（中文版）

④ 《免疫檢查點抑制劑用於進展期胃癌圍手術期治療的中國專家共識》（2024年版）

⑤ Guidelines for the Clinical Application of Immune Checkpoint Inhibitors in Cervical Cancer (2024 Edition)	⑤ 《子宮頸癌免疫檢查點抑制劑臨床應用指南(2024年版)》
⑥ CSCO Guidelines for Endometrial Cancer 2024 Version	⑥ 《CSCO子宮內膜癌診療指南》(2024年版)
⑦ CSCO Guidelines for Cervical Cancer 2024 Version	⑦ 《CSCO宮頸癌診療指南》(2024年版)
⑧ CSCO Guidelines for Ovarian Cancer 2024 Version	⑧ 《CSCO卵巢癌診療指南》(2024年版)
⑨ CSCO Guidelines for Clinical Application of Immune Checkpoint Inhibitors 2024 Version	⑨ 《CSCO免疫檢查點抑制劑臨床應用指南》(2024年版)
⑩ CSCO Guidelines for Gastric Cancer 2024 Version	⑩ 《CSCO胃癌診療指南》(2024年版)
⑪ CSCO Guidelines for Colorectal Cancer 2024 Version	⑪ 《CSCO結直腸癌診療指南》(2024年版)
⑫ Expert Consensus on Pharmaceutical Services for the Clinical Application of Innovative Subcutaneous preparations of antineoplastic drugs (2024)	⑫ 《抗腫瘤藥物創新皮下製劑臨床應用的藥事服務專家共識》(2024年)
⑬ Chinese Expert Consensus on MDT Management of Colorectal Cancer Liver Metastasis (2024 Edition)	⑬ 《結直腸癌肝轉移MDT診治中國專家共識(2024版)》
⑭ Expert Consensus on Immunotherapy for Gastric Cancer Based on PD-L1 Protein Expression Levels (2023 Edition)	⑭ 《基於PD-L1蛋白表達水平的胃癌免疫治療專家共識(2023年版)》
⑮ Expert Consensus on Drug Therapy for Gastric Cancer	⑮ 《胃癌藥物治療專家共識》
⑯ Chinese Guidelines on Standardized Application of Immunotherapy for Lung Cancer (2024 Edition)	⑯ 《中國肺癌免疫治療規範化應用指南(2024版)》
⑰ Expert consensus on the whole-process management of clinical application of immune checkpoint inhibitors for esophageal cancer	⑰ 《食管癌免疫檢查點抑制劑臨床應用全程管理專家共識》
⑱ Practice Guidelines for Off-Label Use of Immune Checkpoint Inhibitors	⑱ 《免疫檢查點抑制劑超說明書用藥實踐指南》
⑲ Expert Consensus on Microsatellite Instability (MSI) Detection Technology.	⑲ 《微衛星不穩定性(MSI)檢測技術專家共識》

4. Honors in 2024

Top 100 Chinese Pharmaceutical Innovation Enterprises

In September 2024, 3D Medicines Inc. was honored to be listed among the "Top 100 Chinese Pharmaceutical Innovation Enterprises" a distinction jointly awarded by Healthcare Executive and independent third-party organizations. This marks the third consecutive year that 3D Medicines has been recognized in this prestigious ranking, highlighting its exceptional innovation capabilities in the field of cancer immunotherapy.

4、 2024年獎項

中國醫藥創新企業100強

2024年9月，思路迪医药股份有限公司榮登由E藥經理人聯合三方獨立機構共同評選出的，「中國醫藥創新企業100強名單」，思路迪醫藥連續三年獲得「中國醫藥創新企業100強」的榮譽，彰顯了在腫瘤免疫治療領域的卓越創新能力。

Top 500 Enterprises in the National SME Innovation and Entrepreneurship Competition

In November 2024, the Qingdao branch of 3D Medicines Inc. (Stock Code: 1244.HK) was selected as one of the "Top 500 Enterprises in the National SME Innovation and Entrepreneurship Competition" during the 9th "Chuangke China" SME Innovation and Entrepreneurship Competition. The event was organized by the Cybersecurity Industry Development Center of the Ministry of Industry and Information Technology (MIIT Information Center), in collaboration with provincial SME authorities and relevant organizations. The company earned this accolade by showcasing the potential and development prospects of its "mRNA Cancer Vaccine Platform R&D Project".

中小企業創新創業大賽全國企業組500強

2024年11月，思路迪医药股份有限公司（思路迪醫藥股份，1244.HK）青島公司於工業和信息化部網絡安全產業發展中心（工業和信息化部信息中心）聯合各省、自治區、直轄市及計劃單列市、新疆生產建設兵團中小企業主管部門（以下統稱省級中小企業主管部門）以及有關單位舉辦的第九屆「創客中國」中小企業創新創業大賽中，通過展示《mRNA腫瘤疫苗平台研發項目》的內在潛力和發展前景，被評選為「中小企業創新創業大賽全國企業組500強」。

Zhiyuan Award – ESG Social Responsibility (S) Pioneer Enterprise Award

On November 29, 2024, 3D Medicines Inc. (Stock Code: 1244.HK) was awarded the "Zhiyuan Award – ESG Social Responsibility (S) Pioneer Enterprise Award" at the 5th Caijing ESG Forum hosted by Caijing Media Group.

致遠獎—ESG社會責任(S)先鋒企業獎

2024年11月29日，思路迪医药股份有限公司（思路迪醫藥股份，1244.HK）於2024年第五屆財聯社企業ESG論壇中獲「致遠獎—ESG社會責任(S)先鋒企業獎」

Best Commercial Return Award (Biotech Category)

On December 17, 2024, 恩維達®, a commercialized product of 3D Medicines Inc. (Stock Code: 1244.HK), was honored with the "Best Commercial Return Award (Biotech Category)" at the 2024 China Biopharmaceutical Industry Chain Innovation Awards Ceremony.ESG

最佳商業回報獎(生物獎)

2024年12月17日，思路迪医药股份有限公司(思路迪醫藥股份，1244.HK)商業化產品恩維達®於2024年中國生物醫藥產業鏈創新風雲榜頒獎典禮中榮獲「最佳商業回報獎(生物獎)」。

ESG

1. ESG concept

3D Medicines is keenly aware of the corporate role and responsibilities in advancing social sustainability. We have been committed to developing highly effective and innovative oncology therapeutics to improve public health outcomes. By continuously striving to enhance our performance in environmental protection, social responsibility, and governance (ESG), we aim to become a trusted world-leading biopharmaceutical company.

2. Management architecture of the Board of Directors

As the highest decision-making body of ESG work, the Board of Directors of the Company is responsible for ESG implementation policies, work strategies, risk identification and the formulation of sustainable goals, as well as the monitoring of the implementation of the ESG work and the annual ESG results.

The Board of Directors appoints the Board Secretariat as the implementation and supervisory body for planning the overall ESG work, identifying and evaluating the Group's ESG-related content, supervising the daily ESG performance and implementation, evaluating ESG risks and establishing an effective internal communication mechanism.

ESG管治

1、 ESG理念

思路迪醫藥深刻意識到企業在推動社會可持續發展中的角色與責任，一直致力於為患者提供高效且創新的腫瘤藥物，為公共健康作出貢獻。我們不斷努力提升在環境保護、社會責任和治理結構方面的表現，力爭成為備受信賴的全球一流生物醫藥公司。

2、 董事會管理架構

公司董事會作為ESG管理的最高決策機構，負責制定並實施ESG政策、制定工作戰略、識別和管理風險以及設定可持續發展目標。董事會監督ESG工作的進展，並對全年成果負責。

董事會辦公室負責實施和監督ESG總體規劃，對集團內的ESG相關內容進行識別和評估，確保公司日常ESG工作得以有效執行，並建立高效的內部溝通機制。

The ESG work team is the actual execution department of the Company's ESG work, which conducts unified overall receipt, collation, and reporting of ESG matters. ESG work team directly communicates with various departments on the implementation and progress of ESG content, and publicly discloses ESG-related events.

ESG工作小組作為執行部門，統一管理並報告所有ESG事項，直接與各部門溝通實施進度，並負責披露相關事件。

All functional departments cooperate with the ESG work team to execute and implement ESG work plans and goals.

公司各職能部門與ESG工作小組密切合作，共同執行並落實ESG工作計劃與目標。

3. Statement of the Board of Directors

1) *Responsibilities of the Board of Directors*

The Board of Directors serves as the supreme governing body for ESG oversight, responsible for formulating the Group's overarching ESG strategy and objectives. It regularly monitors, reviews, and approves ESG initiatives while identifying and assessing material ESG risks and issues. The Board also ensures timely ESG disclosures to stakeholders, proactively reviews and addresses ESG-related incidents, and safeguards the achievement of the Company's sustainable development goals.

2) *ESG execution*

The Company has designated the Board Secretariat as the institutional body responsible for ESG review, oversight, and implementation. Under this structure, the Secretariat has established an ESG Task Force serving as the operational arm. This dedicated unit collaborates closely with cross-functional departments to fulfill core mandates including driving ESG strategic objectives, identifying material risks, and managing the execution progress with accountability mechanisms.

3) *Major ESG topics*

The Company attaches great importance to the identification of major ESG topics, and finally confirm the content of major ESG topics through visits and investigations of various stakeholders and the evaluation of the Company's management.

3、 董事會聲明

1） *董事會責任*

董事會作為ESG治理結構的最高責任機構，負責制定集團的整體ESG策略和目標。董事會定期監控、審查和批准ESG戰略和相關活動，識別並評估重大ESG風險和議題。董事會還負責及時向公眾披露ESG信息，審查和處理ESG相關的負面事件，確保公司的可持續發展目標得以實現。

2） *ESG執行*

公司委派董事會辦公室為ESG活動的審查、監管及執行機構。董事會辦公室下設ESG工作小組，作為具體執行部門，與公司各職能部門緊密協作，共同承擔實現公司ESG戰略目標、識別ESG風險、管理ESG工作具體進展及落實情況等職**責。**

3） *重大性ESG議題*

我們高度重視ESG重大性議題的識別，通過對各利益相關方的走訪調查，以及公司管理層的評估，最終確認公司重大性ESG議題的內容。

4) *ESG risk management*

The Board places strategic emphasis on ESG-related risks, having instituted dedicated personnel for real-time media monitoring. The Company has developed comprehensive risk mitigation strategies encompassing systematic processes for detecting, identifying, assessing, and addressing material exposures, thereby minimizing potential adverse impacts. Through these institutionalized strategies, we ensure methodical advancement toward long-term value creation while maintaining sustainable development trajectories.

4） *ESG風險管治*

董事會高度重視ESG相關風險，並設立專門人員進行輿情監測。公司制定了一系列風險應對策略，包括風險的發現、識別、評估和處理，以盡可能降低ESG風險對公司的負面影響。通過這些措施，公司致力於確保在可持續發展過程中，穩步前進，實現長遠目標。

4. Communication with stakeholders

4、 利益相關方溝通

Stakeholders 利益相關方	Expectation and requirements 期望與訴求	Company response 公司回應	Main communication modes 主要溝通途徑
Customers/ potential customers	R&D innovation Product quality	Study and innovation Platform construction Responsible publicity Responsible operation Quality management	Daily operation Company website Media message Academic conferences Industry forums
客戶／潛在客戶	研發創新 產品品質	研究與創新 研發平台建設 負責任宣傳 責任經營 品質管理	日常運營 公司網站 媒體留言 學術會議 行業論壇
Shareholders and investors	R&D innovation R&D progress Commercialization Information disclosure Shareholder's equity Intellectual property protection Risk governance	R&D and innovation Platform construction Recruitment of commercialization executives Quality management Intellectual property protection Commercial cooperation Responsible operation Supply chain management	General Meeting of Shareholders Investor roadshow Interim conference call Business progress news release Clinical data release and interpretation Securities communication Company website Performance announcement Interim and difficulty financial report Material disclosure
股東及投資者	研發創新 研發進展 商業化 資訊披露公開 股東權益 知識產權保護 風險治理	研發與創新 品質管理 僱傭商業化高管 知識產權保護 商業合作 責任經營 供應鏈管理	股東大會 投資者路演 中期電話會議 業務進展新聞發佈 臨床數據發佈及解讀 券商溝通 公司官網 業績公告 中期及年度財務報告 重大事項披露

Stakeholders 利益相關方	Expectation and requirements 期望與訴求	Company response 公司回應	Main communication modes 主要溝通途徑
Employees	Employee benefit Employee training Employee health and welfare	Employee rights and interests Employee health and safety Employee training and career development Compliance employment Employee equality Employee communication	Team building activities Employee training Performance evaluation Exit interview
員工	員工福利 員工培訓 員工健康與權益	員工權益 員工健康健全 員工培訓與發展 合規僱傭 員工平等 多元化 員工溝通	員工團建活動 員工培訓 績效評估 離職面談
Suppliers	Company procurement Procurement management	Supply chain and supplier management	Daily operation Supplier access Supplier procurement request Supplier audit
供應商	公司採購 採購管理	供應鏈及供應商管理	日常運營 供應商准入 供應商請購 供應商審計
Competitors	Fair competition Win-win cooperation	Responsible operation Commercial cooperation Academic discussion	Intra-industry exchange Industry conference discussion Strategic cooperation Academic Forum
同行業者	公平競爭 合作共贏	責任經營 商業合作 學術論壇	行業內部交流 同行業會議討論 戰略合作 學術會議

Stakeholders 利益相關方	Expectation and requirements 期望與訴求	Company response 公司回應	Main communication modes 主要溝通途徑
Government and supervisory body	Responsible operation Corporate governance Promotion of industry development Sustainable development Social welfare	Responsible operation Emission management Natural resources management Social welfare Business ethics	Government communication Regulatory communication Compliance review and report
政府及監管機構	責任經營 企業管治 促進行業發展 可持續發展 社會公益	責任經營 排放物管理 自然資源管理 社會公益 商業道德	政府溝通 監管溝通 合規審查及報告
Community	Sustainable development Social welfare	Social welfare Emission management Inclusive healthcare Natural resources management	Public welfare activities Internal economizing system
社區	可持續發展 社會公益	社會公益 排放物管理 普惠醫療 自然資源管理	公益活動 內部節約制度

5. Analysis of substantive topics

Substantive topic matrix of the Company

5、 實質性議題分析

本公司實質性議題矩陣



Substantive topic matrix of the Company
本公司實質性議題矩陣

Highly important topics
高度重要性議題

16. R&D and innovation
27. Protection of the interests of shareholders and investors
17. Intellectual property protection
16. 研發與創新
27. 保障股東和投資者利益
17. 知識產權保護
7. Optimized resource management
9. Employee health and safety
20. Drug quality management
7. 優化資源管理
9. 員工健康與安全
20. 藥物品質管理
8. Employee rights and interests
2. Management of hazardous emissions
6. Response to climate change
8. 員工權益
2. 有害排放物管理
6. 應對氣候變化
5. Energy saving
18. Supply chain management
5. 能源節約
18. 供應鏈管理

Moderate important topics
中度重要性議題

22. Responsible marketing
14. Legal employment, equality and diversity
3. Chemical drug management
26. Risk control
22. 負責任行銷
14. 合法僱傭、平等及多元化
3. 化學藥物管理
26. 風險管控
25. Legal and compliant governance
11. Employee welfare and care
24. Economic benefits and financial performance
15. Customer service guarantee
25. 合法合規治理
11. 員工福利與關愛
24. 經濟效益與財務表現
15. 客戶服務保障
1. Sound environmental management system
28. Anti-corruption and clean government
10. Employee communication
19. Win-win cooperation
1. 健全的環境管理體系
28. 反腐倡廉
10. 員工溝通
19. 合作共贏
4. Water resource utilization
12. Employee training
13. Employee salary
23. Social public welfare investment
4. 水資源利用
12. 員工培訓
13. 員工薪酬待遇
23. 社會公益投入

6. Communicate with investors

Since its listing in 2022, the Company has focused on establishing long-term and effective communication mechanisms with investors. In 2024, the Company expanded various ways and channels to establish contact with investors, including media, forums, conferences, hotlines, etc. The Company helps investors understand the latest development and status of the Company through various channels such as roadshows, securities exchange meetings, and performance conferences, and answers the most concerned questions of investors.

During the reporting period, the Company carried out more than 80 communication activities with investors, covering various formats such as investor conferences, investor calls/online communications, and information disclosures on the official website. These efforts actively responded to investors' concerns and enhanced market trust and recognition of the Company.

At the same time, the Company places great importance on interacting with individual shareholders and has enhanced information transparency through digital platforms. By establishing corporate accounts on major trading platforms, the Company promptly discloses information and updates, carefully reviews investors' comments, and responds when necessary.

6、 與投資者溝通

公司自2022年上市以來，注重與投資者展開長期、有效的溝通機制。2024年，我們擴展了多種與投資者建立聯繫的方式及管道，包括媒體，論壇，會議，熱線等方式。我們通過路演、券商交流會、業績發佈會等多種管道幫助投資者瞭解公司最新發展情況與狀態，並解答投資者最關心的問題。

報告期內，投資者溝通會議開展超過80場，涵蓋投資者會議、投資者電話／線上交流、官網信息披露等多種形式，積極回應投資者關切，提升市場對公司的信任度與認可度。

同時，公司高度重視與個人股東的互動，通過數字化平台提升信息透明度。我們通過建立企業帳號形式，在各大交易軟體，及時披露公司資訊及動態，並認真查閱投資者的留言，必要時進行回覆。

I. ENVIRONMENTAL MANAGEMENT

(I) Integrated environmental management

The pharmaceutical sector bears distinctive responsibilities in environmental stewardship, where establishing robust management systems constitutes an industry imperative. 3D Medicines has institutionalized comprehensive environmental governance through policy formulation and measurable targets. Focusing on emission reduction, resource circularity, and energy efficiency controls, we implement process-wide optimizations to systematically enhance environmental management capabilities.

1. Environmental management system

According to relevant laws, regulations, and regulatory systems such as the *Law of the People's Republic of China on the Prevention and Control of Environmental Solid Waste Pollution* and the actual situation, 3D Medicines has formulates and implements an environmental management system with the aim of strengthening hazardous waste management, protecting the ecological environment, safeguarding human health, and maintaining public safety.

In order to further optimize environmental management, 3D Medicines clearly defines its environmental management goals, and promises to continuously reduce environmental pollution, practice resource conservation and recycling, actively carry out energy management and ecological protection, strengthen green supply chain management and environmental risk prevention.

The environmental management measures carried out by 3D Medicines include:

- Periodic Resource Audits: Institutionalize clean production verification with quantified resource efficiency metrics, supported by dedicated R&D funding for green process innovation

- Lifecycle Impact Assessment: Enforce mandatory EIA for capital projects, implementing dual-track management of ecological conservation plans and environmental risk mapping

一、環境管理

（一）綜合環境管理

醫藥行業在環境管理領域承擔特殊責任，構建科學完善的環境管理體系已成為行業核心議題。思路迪醫藥通過制度化建設持續完善環境治理，制定專項政策與可量化目標，重點圍繞污染物減排、資源循環利用、能耗強度管控等關鍵維度實施全流程優化，系統化提升環境管理效能。

1、 環境管理系統

思路迪醫藥依照《中華人民共和國固體廢物污染環境防治法》等相關法律法規及監管制度，結合自身實際，制定並執行環境管理制度，旨在加強危險廢物管理，保護生態環境，保障人體健康，維護公共安全。

為進一步優化環境管理，思路迪醫藥明確了環境管理目標，思路迪醫藥承諾將持續減少環境污染，踐行資源節約與迴圈利用，積極開展能源管理及生態保護，加強綠色供應鏈管理及環境風險防範。

思路迪醫藥開展的環境管理舉措包括：

- 周期性資源審核機制：建立清潔生產核查體系，通過可量化的資源利用率指標優化工藝流程，配套綠色技術研發專項預算

- 全周期環境評估：嚴格執行新建／改擴建項目環境影響評價制度，實施生態保護方案與環境風險識別雙軌管理

- Compliance Audit Framework: Conduct annual environmental due diligence through hybrid monitoring combining facility inspections with IoT-enabled surveillance

- Standardized Management System: Develop governance architecture encompassing policy formulation, risk matrix analysis, capacity building, and KPI tracking to achieve Plan-Do-Check-Act cycle

In 2024, the Company had no major environmental problems or environmental protection punishments.

2. *Emissions management*

3D Medicines attaches great importance to emissions management, strengthens the supervision of pollutant emissions, ensures the standard discharge of wastewater and exhaust gas, standardizes the management and disposal of solid waste, and continuously improves the environmental protection awareness of employees in green emission reduction.

- *Compliant emission*

  3D Medicines Inc. deeply embeds green sustainability principles into corporate operations, rigorously complying with national and local ecological regulations. By building a circular industrial ecosystem, we continuously optimize whole-process clean production management to achieve dual enhancement in waste resource utilization efficiency and comprehensive economic value. Our R&D facilities are equipped with three-waste treatment systems, with emission indicators for wastewater, exhaust gases, and solid wastes consistently exceeding national standards. Through an established continuous environmental management improvement system, we are committed to setting the industry benchmark for eco-conscious practices in biopharmaceuticals.

- 合規審計體系：開展年度環境合規性診斷，通過現場巡檢與數字化監測結合的方式實現環保隱患動態清零

- 標準化管理系統：構建包含政策制定、風險矩陣、能力建設、績效追蹤的環境治理架構，形成PDCA管理閉環

2024年，公司未出現重大環保問題或被環保處罰。

2、 *污染排放管理*

思路迪醫藥重視公司排放物管理，加強污染物排放監管，確保廢水、廢氣達標排放，固體廢物規範化管理與處置，持續提升員工綠色減排的運營環保意識。

- *合規排放*

  思路迪醫藥始終將綠色可持續發展理念深度融入企業運營，嚴格遵循國家及屬地生態環保政策法規。我們通過構建循環型產業體系，持續完善全流程清潔生產管理機制，實現廢棄物資源化利用率和綜合產值效能的雙向提升。公司研發場所全面配備三廢處理系統，廢水、廢氣及固體廢棄物的排放指標均優於國家標準，並建立環境管理能力持續改進體系，致力於打造生物醫藥行業的環保標桿企業。

1) Ambient air
According to the *Functional Zoning of Ambient Air Quality in Shanghai* (HHBF [2011] No. 250), the Company is located in a class II ambient air zone, where the basic pollutants shall be subject to the *Ambient Air Quality Standard* (GB3095-2012) and its revised single secondary standard; while other pollutants shall be subject to the recommended values in Appendix D of *Technical Guidelines for Environmental Impact Assessment – Atmospheric Environment* (HJ2.2-2018) and the *Detailed Explanation of Comprehensive Emission Standards for Atmospheric Pollutants*.

1） 環境空氣
根據《上海市環境空氣品質功能區劃》(滬環保防[2011]250號），所在區域為環境空氣二類區，基本污染物執行《環境空氣品質標準》(GB3095-2012)及其修改單二級標準；其他污染物執行《環境影響評價技術導則大氣環境》(HJ2.2-2018)附錄D和《大氣污染物綜合排放標準詳解》中的推薦值。

2) Surface water environment
According to the *Functional Zoning of Water Environment Quality in Shanghai* (Rev. 2011), the Company is located in a class V water quality area, and subject to the class V standard of the *Surface Water Environment Quality Standard* (GB3838-2002).

2） 地表水環境
根據《上海市水環境品質功能區劃（2011年修訂版）》，所在區域為V類水質區，執行《地表水環境品質標準》(GB3838-2002)V類標準。

3) Exhaust gas emission standard
The exhaust gas emissions are mainly particulate matters, and shall be subject to the *Control Standard of Particulate Matter for Construction* (DB31/964-2016), with the specific indicators shown in Table 18.

3） 廢氣排放標準
廢氣污染物主要為顆粒物，排放標準執行《建築施工顆粒物控制標準》(DB31/964-2016)，具體指標見表18。

4) Wastewater discharge standard
The wastewater discharge shall be subject to the corresponding standards for indirect discharge by biomedical R&D institutions in the *Discharge Standard of Pollutants for Bio-pharmaceutical Industry* (DB31/373-2010) in Shanghai, as detailed in Table 20.

4） 廢水排放標準
廢水排放執行上海市《生物製藥行業污染物排放標準》（DB31/373 – 2010）中生物醫藥研發機構間接排放的相應標準，具體見表20。

5) Solid waste
The general industrial solid waste storage sites shall comply with the requirements of the *Standard for Pollution Control of General Industrial Solid Waste Storage and Disposal Sites* (GB18599-2001) and its amendment in 2013; Hazardous waste storage sites shall comply with the requirements of *Standard for Pollution Control on Hazardous Waste Storage* (GB18597-2001) and its amendment. The storage capacity of hazardous waste shall meet the relevant requirements of the *Notice of Shanghai Municipal Bureau of Ecological Environment on Issuance of the Implementation Plan for Further Strengthening the Prevention and Control of Hazardous Waste Pollution in Shanghai* (HHT (2020) No. 50).

5） 固體廢物
一般工業固廢貯存場所執行《一般工業固體廢物貯存、處置場污染控制標準》(GB18599-2001)及2013年修改單要求；危險廢物場所執行《危險廢物貯存污染控制標準》(GB18597-2001)及修改單要求。危險廢物貯存能力滿足《上海市生態環境局關於印發〈關於進一步加強上海市危險廢物污染防治工作的實施方案〉的通知》(滬環土[2020]50號)相關要求。

- *Management of hazardous waste*

3D Medicines attaches great importance to hazardous waste management, adhering to a rigorous and systematic approach to fulfill environmental protection responsibilities.

- *危險廢物管理*

思路迪醫藥高度重視危險廢物管理，秉持嚴謹負責的態度，構建了一套全面且系統的管理體系，以切實履行環境保護責任。

1) Management Responsibilities
The legal representative serves as the primary responsible party for hazardous waste management.The Biological Safety Committee oversees unified supervision of pollution prevention and control efforts2.

1) 管理責任
公司法人作為危險廢物管理的首要責任人，肩負著整體把控和決策的重任。生物安全委員會成員則擔任監督管理的重要角色，對公司危險廢物的環境污染防治工作實行統一監督，確保各項管理措施落實到位。

2) Key Management Principles
Implementation follows the principles of "unified collection, categorized treatment, centralized incineration, and risk elimination", with continuous advancement toward the goals of "reduction, resource recovery, and harmless treatment".

2) 管理原則
在管理原則方面，思路迪醫藥遵循「統一收集、分類處置、集中焚燒、消除隱患」的方針，將危險廢物管理工作有序推進，並以「減量化、資源化和無害化」作為長期目標，不斷探索和實踐更有效的管理方法。

3) Infrastructure Development

Hazardous waste pollution control is integrated into corporate development plans. Environmentally compliant collection/storage facilities and dedicated equipment are established. Safety officers submit real-time declarations to local environmental authorities and annually register through Shanghai Hazardous Waste Management Information System. Ensure the transparency and legality of management practices. Additionally, the Safety Committee conducts annual comprehensive inspections of hazardous waste collection and transportation facilities as well as storage sites. Any identified issues such as damage are promptly addressed through cleaning and replacement measures to eliminate potential safety hazards.

3) 基礎設施

公司將危險廢物污染防治工作融入公司發展的整體規劃中，積極投入資源建設符合環保要求的收集、貯存場所和專用設施。安全環保管理員負責及時向當地環保局申報公司危險廢物的相關資訊，並每年登入上海市危險廢物管理資訊系統進行申報登記，確保管理工作的透明度和合法性。此外，安委會每年對危險廢物收集、運輸設施和儲存場所進行全面檢修，一旦發現破損等問題，立即採取清理更換措施，消除安全隱患。

4) Transportation Protocols

Licensed transporters designated by environmental agencies handle waste shipments.Non-specialized vehicles must undergo immediate disinfection at centralized disposal sites.The Safety and Environmental Committee signs leakage and spillage prevention agreements with transporters and conducts regular inspections.

4) 運輸管理

在運輸管理上，由當地環保部門指定具有專業資質的運輸公司承擔危險廢物的運送工作。對於沒有專運車輛的情況，要求在危險廢物集中處置場所內及時進行消毒和清潔。公司安委會與運輸單位或個人簽訂防止車輛運輸洩漏、遺撒的協議書，並定期對運輸單位和車輛進行督促檢查，保障運輸過程的安全和環保。

5) Incident Reporting Mechanism

To address potential hazardous waste incidents, 3D Medicines has established a comprehensive accident reporting system. This system categorizes environmental incidents into immediate reports and post-resolution reports. Upon identifying an environmental incident, relevant personnel must submit an immediate report within one hour, followed by a detailed post-resolution report promptly after the incident is addressed. During the collection, transportation, storage, utilization, or disposal of hazardous waste, if a contamination incident or other sudden environmental emergency occurs, the responsible entities and individuals must immediately implement measures to prevent or mitigate pollution risks, notify potentially affected organizations and residents in a timely manner, and report the incident to the local environmental protection authorities where it occurred.

5) 事故報告機制

為了應對可能發生的危險廢物事故，思路迪醫藥建立了完善的事故報告制度。該制度將環保事故分為速報和處理結果報告兩類。一旦發現環保事故，相關人員需在一小時內完成速報；事故處理完畢後，立即上報處理結果報告。在危險廢物的收集、運送、貯存、利用和處置過程中，如發生污染事故或其他突發性污染事故，有關單位和個人應迅速採取措施防止或減輕污染危害，及時向可能受到影響的單位和居民通報情況，並向事故發生地的環保部門報告。

6) Maintenance & Compliance

Annual maintenance checks are conducted on collection/transport facilities and storage areas, with prompt repairs for any identified defects.

Through these comprehensive measures, 3D Medicines strives to achieve efficient, safe, and eco-friendly hazardous waste management, contributing to sustainable development.

6) 維護與合規

年度維護檢查對收集／運輸設施和儲存區域開展，並對發現的缺陷立即修復。

通過以上全方位的管理措施，思路迪醫藥致力於在危險廢物管理領域做到高效、安全、環保，為保護環境和社會可持續發展貢獻力量。

- *Management of other emissions*

In terms of emission management, the Company strictly controls the discharge of various pollutants, including the treatment and disposal of exhaust gas, wastewater, and waste residue. The Company adopts advanced pollution control technique and equipment to effectively reduce pollutant emissions and ensure compliance with relevant regulations and standards. In addition, the Company strengthens source control by optimizing production processes and adopting clean production methods to reduce waste generation.

The solid waste generated by the Company mainly comes from office waste and household waste in the production and operation process. To achieve effective management of office waste and household waste, the Company reduces the impact of waste on the environment through sorted collection. In addition, the Company advocates the use of reusable materials and containers, such as paper and plastic, to reduce waste generation.

In 2024, the Company has further strengthened its waste and emissions management and conducting regular internal supervision and management. Therefore, based on 2022, relevant data was more accurately collected and disclosed.

- *其他排放物管理*

在排放物管理方面，思路迪醫藥嚴格控制各類污染物的排放，包括廢氣、廢水和廢渣的處理和處置。公司採用先進的污染治理技術和設備有效減少污染物的排放，確保符合相關法規標準。此外，公司加強源頭控制，通過優化生產工藝和採用清潔生產方法，減廢棄物的產生。

思路迪醫藥產生的固體廢棄物主要來源於生產經營過程中的辦公垃圾和生活垃圾。為實現對辦公垃圾和生活垃圾的有效管理，公司通過分類回收的方式，降低廢物對環境造成的影響。此外，公司提倡使用可重複利用的材料和容器，例如紙張和塑膠等，從而減少廢棄物的產生。

2024年，思路迪醫藥進一步加強廢棄物及排放物管理，定期進行內部監督及管理，因此，在2022年基礎上，更加精準地統計了相關數據並進行披露。

Indicator **指標**	**Unit** **單位**	**2024** **2024年**	**2023** **2023年**	**2022** **2022年**
Total amount of hazardous wastes 有害廢棄物總量	Ton 噸	**50.42**	43.71	3.16
Hazardous waste discharge density 有害廢棄物排放密度	Ton/million revenue 噸／百萬營收	**0.113**	0.069	0.005

(II) Coordinate energy conservation and emission reduction

3D Medicines acknowledges that resources are fundamental to sustainable societal development. Committed to green and low-carbon principles.

1. Energy saving and consumption reduction

3D Medicines strictly adheres to the provisions of laws and regulations such as the Energy Conservation Law of the People's Republic of China, actively implements the concept of resource conservation in its production and operations, and establishes a systematic energy consumption measurement and monitoring framework to record energy usage data comprehensively. The company has formulated internal policies including the Electricity Conservation Management System and Water Conservation Management System, in alignment with national environmental protection guidelines and its strategic development goals. Through continuous enhancement of energy management mechanisms, 3D Medicines aims to optimize resource allocation and improve energy utilization efficiency.

（二）統籌節能減排

思路迪醫藥深刻理解資源作為人類社會可持續發展的核心物質基礎，始終堅持綠色低碳發展理念，將能源利用與生態文明建設深度融合。

1、節能降耗

思路迪醫藥嚴格遵循《中華人民共和國節約能源法》等法律法規要求，將資源節約理念全面融入生產運營，通過實施能源消耗計量與監測體系，系統性記錄能源使用數據，構建規範化能源管理模式。同時，公司依據國家環境保護政策及自身發展戰略，制定了《節約用電管理制度》和《節約用水管理制度》，持續完善能源管理體系，優化資源配置，全面提升能源利用效率。

Case

In 2024, 3D Medicines further advanced energy conservation through the following initiatives:

1. **Paperless Office Practices**
   Implemented a digital document management system, mandated double-sided printing, and reduced color printing usage.

2. **Waste Recycling Program**
   Deployed categorized recycling stations (paper, batteries, ink cartridges) with incentive mechanisms to promote reuse.

3. **Energy-Efficient Equipment**
   Upgraded 90% office lighting to LED and introduced energy-saving printers with auto-sleep functions.

案例

2024年，思路迪醫藥持續深化節能減排實踐，從日常運營細節入手，通過以下創新舉措實現資源高效利用：

1. **綠色辦公體系優化**
   全面推行電子化行政文件流轉系統，非必要文件採用雙面黑白打印，彩印使用率顯著下降。同步實施無紙化會議方案。

2. **廢棄物循環管理**
   在辦公區設置分類回收站（涵蓋廢紙、電池、墨盒等），建立「以舊換新」激勵機制，提升資源再利用率。

3. **智能節能設備升級**
   更換LED照明燈具覆蓋90%辦公區域，引入自動休眠功能的節能打印機。

Specific energy-saving measures	**具體節能舉措**
The Company supervises laboratory and office staff to carry out energy-saving and consumption reduction work by posting warning signs and other means, for example, turn off lights when leaving, turn off air conditioner, facilities and equipment, and save more resources. Meanwhile, the management conducts supervision from top to bottom and deeply cultivates the concept of energy conservation. For example, we criticized and educated personnel on each floor who have not turned off lighting and air conditioner after work. In this way, we constantly deepen employees' awareness of energy conservation and reduce resource waste. In 2024, the company's total electricity consumption decreased by 11.2% compared to the historical average.	公司通過張貼警示語等方式，督促實驗室、辦公場所員工開展節能降耗工作，隨手關燈、關閉空調、設施設備等，節約資源消耗。同時管理層從上至下進行督導，深植節能理念，對於各樓層人員下班後仍未關閉照明及空調的人員進行批評，深化員工的節能意識，減少資源浪費。2024年，公司用電總量較歷史平均值同比減少11.2%。

2. Energy management

3D Medicines prioritizes energy management as a cornerstone of sustainable development. In strict compliance with the Energy Conservation Law of the People's Republic of China1, the company focuses on reducing energy consumption per unit output through a multi-dimensional approach. By implementing an end-to-end energy monitoring system spanning R&D, production, and logistics, real-time data analysis drives continuous optimization of energy usage patterns3. Standardized energy audits and periodic equipment efficiency evaluations, demonstrating corporate leadership in advancing ecological civilization.

In 2024, the Company urged employees to save energy by posting warning signs, turning off lights, air conditioner and other equipment when leaving. We have established dedicated administrative personnel responsible for monitoring and regulating air conditioning temperatures, ensuring continuous maintenance within the range of 24-26°C, The management also supervised and criticized personnel on each floor who have not turned off lighting and air conditioner after work, deepening their energy-saving awareness, reducing energy waste, and achieving a significant reduction in energy consumption.

2、 能源管理

思路迪醫藥深刻認識能源管理對可持續發展的重要價值，嚴格遵循《中華人民共和國節約能源法》，以降低單位產值能耗為核心目標，系統性推進節能增效工作。通過建立覆蓋研發、生產、物流的全鏈條能源監測體系，公司將節能管理深度融入日常運營，實現能耗數據實時採集與動態優化，為經濟社會的綠色轉型提供企業實踐樣本。

2024年，公司通過張貼警示語的方式，督促員工節省能源，隨手關燈、空調等設備。我們設立專門的行政人員，負責監督管理空調溫度，保證空調溫度持續保持在24-26度之間。管理層亦會進行督導，對於各樓層人員下班後仍未關閉照明及空調的人員進行批評，深化員工的節能意識，減少能源浪費，從而實現能耗下降。

Indicator 指標	Unit 單位	2024 2024年	2023 2023年	2022 2022年
Total electricity consumption 用電總量	Kilowatt-hour 千瓦時	**731,805.5**	723,926	1,134,615
Energy efficient 能源效率	kWh/RMB10,000 revenue 千瓦時／萬元營收	**16.42**	11.40	20.00

Note: The statistical data above involve 3D Medicines and its physical production subsidiaries in China.

說明：上述數據統計範圍為思路迪醫藥及境內各生產實體子公司。

3. Water resources management

Strictly abiding by the provisions and requirements of relevant laws and regulations such as the *Water Law of the People's Republic of China*, 3D Medicines advocates the rational use of water resources, continuously improves the recycle rate of water resources, improves the water-saving awareness of employees by promoting the concept of water conservation, so as to boost the construction of water-saving industry.

During the reporting period, the Company valued the use and consumption of resources from management to grass-roots employees, and we reduced water resource consumption through methods such as posting warning signs and management supervision.The company's total water consumption in 2024 decreased by 20% compared to the previous year.

3、 水資源管理

思路迪醫藥嚴格遵守《中華人民共和國水法》等相關法律法規的規定和要求，宣導合理利用水資源，持續提高水資源的重複利用率，通過宣傳節水理念，提升員工的節水意識，推進建設節水型產業。

報告期內，公司從管理層到基層員工重視資源的使用和消耗，我們從警示語的張貼，管理層監督等方式，降低我們的水資源消耗。2024年，公司總耗水量較上年降低20%。

Indicator 指標	Unit 單位	2024 2024年	2023 2023年	2022 2022年
Municipal water supply consumption 市政供水用量	m^3 立方米	2,168	2,735.70	10,891.00
Barrelled water consumption 桶裝水用量	m^3 立方米	4.95	28.68	25.13
Bottled water consumption 瓶裝水用量	m^3 立方米	25.44	4.87	0.88
Total water consumption 耗水總量	m^3 立方米	2,198.39	2,769.20	10,917.01
Water consumption intensity 水耗強度	m^3/RMB10,000 revenue 立方米／萬元營收	0.05	0.04	0.19

Note: (1) Water efficiency can reflect the revenue per ton of water resource output, namely, the larger the output value per unit of water resource, the higher the water efficiency.

(2) The annual revenue data of 3D Medicines is from the H-share 2024 Annual Results Announcement.

(3) The data only involves 3D Medicines and its main subsidiary factories in China.

說明：(1) 水資源效率體現每噸水資源產出的營收，單位水資源的產值越大，水資源效率越高。

(2) 思路迪醫藥各年度萬元營收資料，來自H股2024年度全年業績公告。

(3) 資料僅包含思路迪醫藥及境內主要分子公司工廠。

4. Material management

3D Medicines specializes in pharmaceutical R&D and clinical trials, with material usage primarily concentrated on drug formulation development and experimental research. In alignment with China's Dual Carbon Strategic Initiative (carbon peak and carbon neutrality), the company implements comprehensive controls over pharmaceutical raw materials and packaging supplies to minimize waste, while optimizing material reuse rates and ensuring regulated recycling of non-recyclable materials. Through these measures, we achieve synergistic optimization of resource efficiency and environmental protection while maintaining pollution-free operations.

According to the 2024 annual operating data, the company has outsourced full lifecycle management of packaging materials – including production, processing, and final disposal – to certified third-party specialists, thereby eliminating direct consumption metrics for packaging resources within our operational scope.

4、 材料管理

思路迪醫藥核心業務聚焦於藥品研發及臨床試驗領域，材料使用場景主要集中於藥物製劑開發及實驗研究環節。為積極響應國家「雙碳」戰略部署，公司通過強化對藥品原料、包裝耗材的全流程管控力度以減少資源浪費，同步提升包裝材料的循環使用頻率，針對不可重複利用材料實施規範化回收處理。在確保生產運營安全環保的前提下，實現資源利用效能與環境保護效益的協同優化。

根據2024年度運營數據顯示，企業已將包裝材料全生命周期管理（包括生產加工與終端處置）交由第三方專業機構實施，因此公司自身不產生包裝材料消耗數據。

(III) Responding to the "Dual Carbon" strategy

3D Medicines proactively integrates national policies into its sustainability framework, embedding ecological protection mechanisms across its full operational chain. The company rigorously implements systematic control mechanisms for greenhouse gas emissions, operating in full compliance with China's "Dual Carbon" strategic objectives to ensure policy-aligned environmental stewardship

1. Protect green homeland

3D Medicines constantly improves the prevention and control measures of air pollution to avoid negative impact on the environment, and strictly abides by the *Law of the People's Republic of China on the Prevention and Control of Air Pollution* and other laws and regulations; in addition, we also take low-carbon development as an important driving force to improve quality and efficiency under the new normal, strictly control the total emissions of greenhouse gases, and enhance the low carbon competitiveness.

The greenhouse gas emission generated within the physical boundaries of production, operation and office of 3D Medicines mainly includes two types of direct emission and indirect emission. The scope of cooperate operation does not involve direct emission sources; the main indirect source of emissions is purchased electricity.

（三）回應「雙碳」戰略

思路迪醫藥深度貫徹國家戰略方針，將可持續發展理念深度融入全業務鏈條，通過建立環境生態保護長效機制，嚴格執行溫室氣體排放的系統性管控措施，全面遵循國家「雙碳」戰略目標實施路徑。

1、 守護綠色家園

思路迪醫藥不斷完善大氣污染防治措施，避免對環境產生影響，公司嚴格遵守《中華人民共和國大氣污染防治法》等法律法規的規定和要求，將低碳發展作為新常態下公司提質增效的重要動力，嚴格控制溫室氣體的排放總量，提升企業的低碳競爭力。

思路迪醫藥在生產、經營和辦公的物理邊界內產生的溫室氣體排放，主要包括直接排放和間接排放兩種類型。其中企業運營範圍不涉及直接排放源；間接排放源主要為外購電力。

No. 序號	Indicator 指標	Unit 單位	2024 2024年	2023 2023年	2022 2022年
1	Direct emissions (Category 1) 直接排放（範疇1）	tCO_2e 噸二氧化碳當量	**–**	–	3,087.61
2	Indirect emissions (Category 2) 間接排放（範疇2）	tCO_2e 噸二氧化碳當量	**417.35**	412.85	659.21
3	Total GHG emission 溫室氣體排放總量	tCO_2e 噸二氧化碳當量	**417.35**	412.85	3,746.82
4	GHG emission intensity 溫室氣體排放強度	tCO_2e/RMB1 million revenue 噸二氧化碳當量／百萬元營收	**0.94**	0.65	6.60

Note: (1) Direct emissions (Category 1) refer to the greenhouse gas emissions from the combustion activities of fossil energy, such as coal, natural gas and oil and industrial production processes;

說明：(1) 直接排放（範疇1）是指煤炭、天然氣、石油等化石能源燃燒活動和工業生產過程等產生的溫室氣體排放；

(2) Indirect energy emissions (Category 2) refer to greenhouse gas emissions from the purchased electricity and heat;

(3) The accounting of calculations is based on the *HKEX Environmental, Social and Governance (ESG) Reporting Guide*, and the National Development and Reform Commission's *Guideline for Accounting and Reporting Greenhouse Gas Emission of Other Industrial Enterprises*.

(2) 能源間接排放(範疇2)是指因外購的電力和熱力等所導致的溫室氣體排放；

(3) 計算依據《香港交易所環境、社會及企業治理匯報指南》、國家發展改革委員會發佈的《工業其他行業企業溫室氣體排放核算方法與報告指南》進行核算；

2. Response to climate change

Against the backdrop of escalating global climate challenges, companies are actively seizing opportunities in climate transition. In line with this trend, our organization conducted systematic climate risk identification and assessment in 2024, guided by the Task Force on Climate-related Financial Disclosures (TCFD) framework. This process entailed establishing a comprehensive climate governance structure across business value chains. Through the development of multidimensional risk assessment models, we identified climate vulnerability hotspots across operational segments and formulated tailored mitigation strategies. Concurrently, we are advancing decarbonization initiatives through energy efficiency upgrades and clean technology adoption, with a clear target to reduce lifecycle carbon emissions intensity. Going forward, we will continue refining our climate management framework to strengthen sustainable development capabilities and fulfill environmental stewardship commitments.

2、 應對氣候變化

在全球氣候變化挑戰持續深化的背景下，企業積極把握氣候轉型中的發展機遇。基於此，我司於2024年參照氣候相關財務信息披露工作組(TCFD)框架要求，系統開展氣候風險識別與評估工作，搭建覆蓋全價值鏈的氣候管理體系架構。通過建立多維度的風險分析矩陣，精準定位業務單元的氣候敏感度，制定差異化的適應策略方案。同步實施碳達峰行動路線圖，加速推進能源結構優化與綠色技術創新應用，有效降低運營全周期碳排放強度。未來將持續完善氣候治理機制建設，強化環境責任履行能力，為企業可持續發展提供長效支撐。

Risk name 風險名稱	Risk description 風險描述	Solutions 應對措施
Policies and regulations	The government has issued new policies and regulations to address climate change and strengthen the compliance requirements of environmental management.	Closely follow up changes in climate change related policies and regulations, and establish a sound compliance management system; regularly evaluate the impact of policy and regulatory risks on the Company, develop corresponding risk response strategies, and reduce the adverse effects of risks.
政策與法規	政府出台新的政策法規，以應對氣候變化並加強環境管理的合規性要求。	密切關注氣候變化相關政策和法規的變化，建立健全的合規管理系統；定期評估政策與法規風險對企業的影響，制定相應的風險應對策略，降低風險帶來的不利影響。
Reputation	A company's actions on climate change that are not aggressive enough or are perceived to have a negative impact on the environment can lead to a negative public perception of it, which can affect the company's reputation and image.	Take measures to reduce carbon emissions, improve energy efficiency, or promote sustainable development practices; develop and implement clear sustainable development strategies, strengthen environmental management, improve transparency, and effectively communicate with stakeholders.
聲譽	企業在應對氣候變化方面的行動不夠積極或被認為對環境造成了負面影響，可能會導致公眾對其產生負面看法，從而影響企業的聲譽和形象。	採取措施減少碳排放、提高能源效率或推廣可持續發展實踐；制定並實施明確的可持續發展戰略、加強環境管理、提高透明度、與利益相關者進行有效溝通。
Market risks	Climate change affects energy price fluctuations and pharmaceutical production costs; climate change may lead to changes in the prevalence patterns of certain diseases, thereby affecting the market demand for drugs.	Strengthen market monitoring and analysis, optimize supply chain management, increase R&D investment, promote green development, and enhance competitiveness and risk resistance.
市場風險	氣候變化影響能源價格波動，影響醫藥生產成本；氣候變化可能導致某些疾病的流行模式發生改變，從而影響藥品的市場需求。	加強市場監測和分析，優化供應鏈管理，加大研發投入，推動綠色發展，以提高自身的競爭力和抗風險能力。

Risk name 風險名稱	Risk description 風險描述	Solutions 應對措施
Technical risks 技術風險	As the impact of climate change intensifies, new technological standards and regulations may emerge, and existing technologies may not be able to adapt to the new challenges brought about by climate change. 隨著氣候變化的影響加劇，可能會出現新的技術標準和規範，現有技術可能無法適應氣候變化帶來的新挑戰。	Strengthen technological research and innovation, pay attention to changes in technological standards, actively engage in technological cooperation and exchange, and pay attention to the protection of intellectual property rights. 加強技術研發和創新，關注技術標準的變化，積極開展技術合作和交流，同時注意知識產權的保護。
Acute physical risks 急性實體風險	Physical losses and risks resulting from unexpected events, such as extreme climate events, natural disasters, and environmental accidents (e.g., typhoons, rainstorms, floods). 由極端氣候事件、自然災害、環境事故（例如颱風、暴雨、洪水）等突發事件所導致的實體損失和風險。	Establish an emergency response mechanism, strengthen the anti-disaster ability of infrastructure, establish flexible supply chains, optimize storage conditions, and develop emergency plans. 建立應急回應機制，加強基礎設施的抗災能力、建立靈活的供應鏈、優化倉儲條件、制定應急預案。
Chronic physical risks 慢性實體風險	Physical losses and risks resulting from the long-term and progressive effects of climate change (e.g. sustained high temperature, drought and sea level rising). 由氣候變化長期、漸進性的影響（如持續高溫、乾旱、海平面上升）所導致的實體損失和風險。	Develop long-term strategic plans, conduct comprehensive risk assessment, and analyze the potential impacts of chronic physical risks on the enterprise; strengthen monitoring and early warning of climate change and environmental change. 制定長期戰略規劃，開展全面的風險評估，分析慢性實體風險對企業的潛在影響，加強對氣候變化和環境變化的監測和預警。

3. Green and low-carbon operation

3D Medicines Inc. adheres to the principle of sustainable development and vigorously pursues a low-carbon transformation strategy. By establishing an integrated green management mechanism spanning R&D, manufacturing, and office operations, we have embedded eco-friendly practices throughout the value chain. A standardized environmental training program combined with paperless office initiatives has been implemented to enhance employees' ecological awareness.

- *Environmentally friendly and energy-saving buildings*

  3D Medicines Inc. has systematically implemented environmental protection measures across all value chain stages. During lab construction, eco-compliant building materials and high-performance soundproofing/thermal insulation systems were adopted to minimize building energy consumption. In production, energy-efficient equipment and renewable energy sources were integrated to enhance energy utilization efficiency. By optimizing manufacturing processes, waste generation was reduced, while a comprehensive waste classification and recycling system was established to promote resource conservation.

3、 綠色低碳運營

思路迪醫藥秉持可持續發展理念，全面推進綠色低碳轉型戰略。通過構建全場景綠色管理機制，將環境友好型實踐深度融入研發、生產及辦公全價值鏈環節。我們建立常態化環保培訓體系，推行無紙化辦公模式，持續強化全員生態保護意識。

- *環保節能建築*

  思路迪醫藥從全價值鏈環節入手系統性推進環境保護工作。在實驗設施建設中採用符合環保要求的建築材料，集成高性能隔音隔熱系統，最大限度降低建築能耗；生產環節全面部署節能設備並引入清潔能源，持續優化能源利用效率。通過改進生產工藝流程減少廢棄物產生量，同步實施垃圾分類處理與回收利用體系，構建資源節約型生產模式。

Laboratory fresh air risk control system of 3D Medicines (Beijing)
思路迪(北京)實驗室新風控制系統

Sewage treatment system of 3D Medicines
思路迪醫藥污水處理系統

- *Advocate low-carbon life*

  3D Medicines Inc. has established a systematic environmental education program to promote eco-conscious office practices and low-carbon lifestyles among employees. The company has fully transitioned to paperless operations by implementing intelligent information management systems, enabling digital workflows for approvals and reimbursement processes to minimize resource consumption. Energy conservation measures include the deployment of energy-efficient lighting across office areas, standardized HVAC usage protocols, and installation of water-saving triple-spout faucets in laboratories. Visible energy-saving signage and sustainability-themed initiatives are integrated into daily operations to reinforce environmental stewardship values.

- *宣導低碳生活*

  思路迪醫藥構建常態化環保教育體系，通過多維度宣傳引導員工踐行綠色辦公與低碳生活方式。公司全面推進無紙化辦公轉型，搭建智能化信息管理平台，實現線上審批、報銷流程全數字化運作，最大限度降低辦公資源消耗。在能源管理方面，辦公區域全面採用高效節能照明系統，制定空調使用規範以減少能源浪費，並在實驗室區域配置節水型三聯水龍頭裝置，優化水資源利用效率。通過設立醒目節能標識、組織綠色生活倡導活動等方式，持續強化員工的環保責任意識。

4. Green supply chain management

Green supply chain management is a critical component of environmental governance in biopharmaceutical enterprises. 3D Medicines Inc. has established a supplier sustainability assessment framework to collaborate with industry partners in building a shared environmental governance mechanism. The company conducts regular environmental capacity audits of suppliers, promotes clean production process upgrades among chemical API suppliers, and advances green supply chain development through collective efforts to minimize the environmental impact across the entire supply chain.

4、 綠色供應鏈管理

綠色供應鏈管理是生物醫藥企業環境治理的關鍵模塊。思路迪醫藥通過建立供應商可持續發展評估體系，協同產業鏈夥伴構建環境責任共治機制。公司定期開展供應商環保能力審計，推動化學原料藥供應商實施清潔生產工藝升級，推動綠色供應鏈建設，共同努力減少整個供應鏈的環境影響。

II. INNOVATIVE R&D

1. R&D management system

As an innovative pharmaceutical company, R&D capability has always been the core competitiveness of 3D Medicines. Therefore, we are committed to establishing a comprehensive R&D management system, providing prerequisites and important guarantees for the improvement of our R&D capabilities.

In terms of R&D management system, the Company, guided by unmet clinical needs, always performs drug R&D management with high-quality standards and continuously improving R&D management policies, ensuring that the products under study have sufficient clinical value worth exploring from beginning to end. During the reporting period, in order to achieve more efficient R&D management, improve innovation level and competitiveness, the Company established a new R&D center to manage four functional departments, responsible for the R&D and management of chemical drugs, biomacromolecules, mRNA tumor vaccines and new products. The R&D center is directly managed by Dr. Gong Zhaolong, Chairman and CEO of the Company, to further improve the efficiency and effectiveness of R&D management.

2. Innovation platform construction

The Company has established a variety of drug R&D platform and continued to explore in the field of chronic cancer treatment. Relying on the Company's proprietary R&D platform, the Company can carry out preclinical R&D activities, including medicinal chemistry synthesis, drug activity screening, drug cell function study, drug biochemical study and biomolecule detection.

The Company's R&D platform has robust capabilities in molecular screening and design, enhancing the success rate of advancing molecules from preclinical research to market approval. This enables the development of innovative therapeutics and supports the pipeline assets built around key pathways and targets.

二、創新研發

1、 研發管理系統

思路迪醫藥作為一家創新型醫藥企業，研發能力始終是公司的最核心的競爭力。因此，本集團始終致力於建立一套完善的研發管理系統，為公司研發能力的提升提供先決條件和重要保障。

在研發管理系統上，公司一直以未滿足的臨床需求為導向，以高質量的標準和不斷完善的研發管理政策進行藥物的開發與研究管理，保證在研產品從始至終擁有充分值得探索的臨床價值。報告期內，公司為實現更高效的研發管理，提高創新水準和競爭力，新成立研發中心並管理四個職能部門，分別負責化學藥物的研發與管理，生物大分子的研發與管理，mRNA腫瘤疫苗的研發和管理以及新產品開發的研發與管理，研發中心由公司董事長兼CEO龔兆龍博士直接管理，進一步提升研發管理的效率及有效性。

2、 創新平台建設

我們建立多種藥物研發平台，在腫瘤慢病化治療領域不斷深入探索。依託專有研發平台，我們能夠開展臨床前研發活動，包括藥物的化學合成、藥物活性篩選、藥物細胞功能研究、藥物生化研究及生物分子檢測。

本公司研發平台擁有強大的分子篩選及設計能力，可提高分子從臨床前研究推進至上市的成功幾率，實現創新的治療方法及支持圍繞關鍵通路及靶點構建的管線資產。

The Company's R&D centers in Shanghai and Beijing include large and small molecule platforms, cell line screening platforms, and compound screening platforms, mRNA R&D platforms, etc. Based on the needs of our innovative R&D initiatives, we have newly established a synthesis and screening platform for ionizable cationic lipids – the key component in lipid nanoparticles (LNP) – to support the development of our nucleic acid drug pipeline.

我們於上海及北京的研發中心包括大小分子平台、細胞系篩選平台、化合物篩選平台、mRNA研發平台等。其中我們新建立了脂質納米微球(LNP)中關鍵組分可電離陽離子脂質的合成和篩選平台，用於支持我們核酸藥物管線的開發。

The Company has hundreds of commercial tumor cell lines from ATCC, ECACC, JCRB and RIKEN, the world's four major cell banks. It covers cancer types with high prevalence in the United States, Europe and Asia, such as lung cancer, liver cancer, colon cancer, gastric cancer, esophageal cancer and breast cancer. This enables broader, more effective and more convenient screening of candidate drugs in early preclinical R&D, and these samples also demonstrate significant advantages in the development of tumor biomarkers.

我們擁有來自全球四大細胞庫ATCC、ECACC、JCRB及RIKEN的數百種商業性腫瘤細胞系。細胞腫瘤的來源涵蓋美國、歐洲及亞洲人群中患病率高的腫瘤類型，例如肺癌、肝癌、結腸癌、胃癌、食管癌及乳腺癌，可在早期臨床前研發中提供更廣泛、更有效及便捷的候選藥物篩選，而該等樣品在腫瘤生物標誌物的開發中亦顯示出顯著的優勢。

3. Construction of R&D team

R&D capability is the core asset of our Company, and outstanding R&D professionals are instrumental in driving the company's rapid and sustainable growth. We are committed to building a high-caliber, experienced, as well as high-potential R&D team. In terms of the overall composition of our R&D personnel, 10% hold doctoral degrees, while 36% hold master's degrees. Additionally, we place great emphasis on nurturing young R&D talents, with employees under the age of 30 accounting for 23% of our R&D workforce.

3、 研發隊伍建設

研發能力是公司的核心資產，優秀的研發人員可以幫助公司更快更好地發展。我們致力於建設一支高品質、富有經驗同時具有潛力的研發團隊。從整體研發人員的構成來看，具有博士學位的研發人員佔比10%，碩士佔比36%。我們亦注重年輕研發人員的培養，在研發人員中30歲以下的僱員可佔到23%。

Among R&D personnel:

研發人員中：



4. R&D and industrialization base

The Company is actively advancing the enhancement of R&D and production capabilities, committed to establishing an integrated R&D-production industrial model. We are constructing internal production facilities in Xuzhou City, Jiangsu Province, which encompass the complete drug development process for both chemical and biological agents. The manufacturing systems and facilities fully comply with current Good Manufacturing Practice (cGMP) standards to meet stringent global requirements. To address the substantial demand for pharmaceuticals post-commercialization, we have secured land use rights for a 65,637.97-square-meter site in Xuzhou. With the acquisition of the construction permit, the development of the new production facility in Xuzhou has now commenced.

4、 研發與產業化基地

公司正積極推進研發與生產能力的提升，致力於構建研產一體化的產業模式。我們在江蘇省徐州市建設內部生產設施，涵蓋化學藥和生物製劑的完整藥物開發流程，其製造系統和設施均符合現行藥品生產質量管理規範(cGMP)，以滿足全球嚴格標準。為滿足未來商業化後對藥品的龐大需求，我們已獲得位於徐州、總面積達65,637.97平方米的土地使用權。目前，施工許可證已獲批，徐州新生產設施的建設工作已正式啟動。

5. Business cooperation

The Company always maintains an open and win-win philosophy in cooperation, draws on each other's strengths utilizing our mature product R&D experience and advantages, discusses new technologies and ideas with partners, and improves the commercial competitiveness of the Company and partners through cooperation, building a sustainable upstream and downstream cooperation model. During the reporting period, the Company signed cooperation agreements with SINO-CELL BIOMED, and Novatim to cooperate in drug R&D. We completed licensing cooperation with Glenmark, granting exclusive licensing rights to the development and commercialization of 恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1) for tumor indications in India, Asia Pacific (excluding Singapore, Thailand and Malaysia), the Middle East and Africa, Russia, CIS and Latin America, in order to benefit patients in more parts of the world.

5、 商業合作

思路迪醫藥在合作方面始終保持著開放共贏的理念，利用自身成熟的產品研發經驗與優勢，與合作夥伴進行優勢互補，討論新技術新想法，並通過合作提高公司及合作夥伴商業競爭力，構建可持續發展的上下游合作模式。報告期內，公司分別與華賽伯曼及科弈藥業簽訂合作協議，合作開展藥物研發。與Glenmark完成授權許可合作，授予其對恩維達®（Envafolimab，恩沃利單抗注射液）在印度、亞太地區（除新加坡，泰國，馬來西亞）、中東和非洲、俄羅斯、獨聯體和拉丁美洲的腫瘤適應症開發及商業化獨家許可權益，以求幫助世界更多地方的患者獲益。

6. Drug accessibility

We are committed to ensuring that every patient has access to optimal treatment. Our mission is to address unmet clinical needs by developing innovative and differentiated therapies. Guided by this principle, we prioritize accelerating clinical trials, expediting drug approvals, and expanding accessibility to enhance the efficacy and reach of our products, ultimately benefiting broader populations.

6、 藥物可及性

我們一直希望可以讓每一個患者都可以得到最優的治療，我們的使命是填補未滿足的臨床需求，研製創新且有差異化價值的藥物。因此，我們以未滿足的臨床需求為導向，加速臨床試驗及藥物上市，擴展藥物普及率等方面提高產品的優效性、可及性，力求可以廣利於眾。

During the reporting period, we actively pursued global partnerships to expand the availability of our therapies. In early 2024, we entered an exclusive licensing agreement with India's Glenmark Pharmaceuticals, granting rights to develop and commercialize our oncology therapies in India, the Asia-Pacific region (excluding Singapore, Thailand, and Malaysia), the Middle East and Africa, Russia, CIS countries, and Latin America. This collaboration aims to bring life-saving treatments to patients in developing and underserved regions.

報告期中，我們積極謀求藥物出海的相關合作，並於2024年初，與印度Glenmark公司完成授權許可合作，授予其對恩維達®(Envafolimab，恩沃利單抗注射液)在印度、亞太地區(除新加坡，泰國，馬來西亞)、中東和非洲、俄羅斯、獨聯體和拉丁美洲的腫瘤適應症開發及商業化獨家許可權益，以此使我們的藥物可以惠及更多國家尤其是一些發展中國家和欠發達國家，以此使更多需要幫助的人可以從我們的藥物中獲益。

In 2024, we also partnered with multiple biotech companies to advance cutting-edge technologies, including mRNA platforms, tumor-infiltrating lymphocyte (TIL) therapies, CAR-T cell therapies, and antibody-drug conjugates (ADCs), as well as exploring combination strategies with 恩維達® (Envafolimab, subcutaneous PD-L1 inhibitor). Leveraging our expertise and collaborative networks, we strive to diversify our pipeline and deliver transformative solutions to patients.

2024年度，我們亦與多家生物公司合作，共同開展包括mRNA, TIL, CAR-T以及ADC藥物的開發或與恩維達®(Envafolimab，恩沃利單抗注射液)聯用。利用自身優勢，與其他公司合作，積極探索世界前沿醫藥技術領域，豐富產品的多樣化更多地幫助我們的患者受益。

In 2024, 恩維達®, the world's first subcutaneously injected PD-L1 inhibitor, has been approved and commercialized in China. It is now available in over 3,000 hospitals and 763+ retail pharmacies across 30 provinces and 305 cities. Furthermore, 恩維達® has been included in the reimbursement lists of 36 city-level "Huiminbao" programs (government-supported supplementary insurance schemes), significantly reducing out-of-pocket costs for cancer patients.

商業化發展中，恩維達作為全球首個皮下注射PDL1首先在中國獲批，在中國30個省，超過305個城市，逾3,000家醫院及763+個藥店銷售。恩維達®已被納入中國36個城市「惠民保」特定高額自費藥品目錄。

7. Intellectual property protection

At the beginning of the company's establishment, in accordance with the standards of intellectual property management, the company gradually established intellectual property management systems such as the "Patent Management System", "Trademark Management System", and "Copyright Management System", and continuously modified, supplemented, and improved them according to the company's development during subsequent operations. In 2024, the company adjusted and improved the provisions of the "Patent Management System" based on its current development situation to adapt to the company's current management regulations.

7、 知識產權保護

在公司創立之初，根據知識產權管理的標準，逐步建立了《專利管理制度》《商標管理制度》《著作權管理制度》等知識產權管理制度，並在後續的經營中根據公司的發展情況不斷修改、補充和完善。2024年，本公司根據公司目前的發展情況，調整和完善《專利管理制度》的規定，以適應公司目前的管理規定。

By the end of 2024, the company had accumulated 36 patents, 86 registered trademarks, and 28 copyrights. In 2024, the company newly applied for 6 patents and 16 trademarks. In 2024, the company was granted 4 patents and 1 trademark was registered.

至2024年底，公司累計獲取專利36件，註冊商標86件，著作權28件。2024年公司新申請專利6件，新申請商標16件。2024年公司授權專利4件，註冊商標1件。

III. QUALITY MANAGEMENT

1. Quality management system

Our company strictly complies with relevant laws and regulations such as the "Drug Administration Law of the People's Republic of China," the "Measures for the Supervision and Administration of Drug Production," and the "Measures for Drug Registration Management." We conduct research and production of new drugs in accordance with the "Good Manufacturing Practice (GMP)," "Good Clinical Practice (GCP)," and "Good Laboratory Practice (GLP)."

As the company operates under a contract manufacturing model and currently has no actual production operations, there is no established occupational safety organization system or safety production protocols. However, the company has implemented the "Standard Operating Procedures for Contract Drug Manufacturing," conducting quality audits of contracted manufacturers every six months. To ensure drug quality and safety, the company performs on-site supervision and inspections of contracted manufacturers, guided by the "Standard Operating Procedures for On-Site Supervision of Contract Drug Manufacturing." All critical processes, quality control laboratories, warehousing systems, and utilities at contracted production facilities are inspected every two quarters. In 2024, the company did not incur any losses due to work-related injuries among employees in production roles. The company currently maintains no production equipment and therefore has no policies regarding equipment depreciation, retirement, or systems for equipment management and maintenance.

三、品質經營

1、 品質管理系統

本公司嚴格遵守《中華人民共和國藥品管理法》《藥品生產監督管理辦法》及《藥品註冊管理辦法》等相關法律法規的規定，並按照《藥品生產品質管理規範(GMP)》《藥物臨床試驗品質管理規範(GCP)》和《藥品非臨床試驗管理規範(GLP)》進行試驗新藥的研究與生產。

公司為委託生產模式，暫無實際生產操作，故暫無安全生產組織體系、安全生產制度等。公司具有《藥品委託生產標準管理規程》，每半年對受託生產商進行一次品質審計。此外本公司為了保證藥品的品質安全，對受託生產商進行現場監督檢查，具備《藥品委託生產現場監督檢查標準管理規程》，每兩個季度對受託生產企業的所有關鍵工序、品質控制實驗室、倉儲系統、公用設施進行一次檢查。2024年，公司沒有發生員工在生產操作崗位上產生工傷造成的損失。公司暫無生產設備，故暫無設備的折舊和報廢政策，無生產設備管理及維護制度。

2. Quality control

Our company has established a comprehensive quality management system in strict accordance with the latest national regulations, including the *"Regulations on Supervising and Managing the Implementation of Drug Quality and Safety Responsibilities by Marketing Authorization Holders"* (No. 126, 2022) and the *"Announcement of the National Medical Products Administration on Strengthening the Supervision of Contract Manufacturing by Drug Marketing Authorization Holders"* (No. 132, 2023). The system encompasses quality assurance protocols for the entire drug production process, such as *Document Management Procedures*, *Employee Training Management Procedures*, *Supplier Management Procedures*, *Contract Drug Manufacturing Management Procedures*, *Drug Market Release Management Procedures*, *Product Sales Management Procedures*, and *Customer Complaint Handling Procedures*. Additionally, the company has implemented *Corrective and Preventive Action (CAPA) Management Procedures* to analyze, assess, and investigate identified or potential non-conformities throughout the product lifecycle and management processes. Corresponding corrective and preventive measures are taken to eliminate root causes, prevent recurrence, and achieve continuous improvement in product processes, quality risk control, and the quality management system.

Our products are pharmaceuticals, and the quality management system for contract drug manufacturing has passed regulatory inspections by the National Medical Products Administration (NMPA), obtaining the *Drug Manufacturing License* issued by the NMPA.

3. Quality training

The company has conducted multiple training sessions for key quality management personnel, covering topics such as quality standards, process technologies, R&D techniques, and pharmacovigilance. In 2024, Sichuan Silu Kangrui Pharmaceutical Co., Ltd. (MAH), as the primary production division, completed a total of 15 training sessions: 5 on regulatory compliance, 2 on technical skills, 2 on operational workflows, 1 on contractual obligations, and 1 on role-specific responsibilities. Each session lasted approximately 1 hour, involving 468 participants.

2、 品質把控

本公司嚴格按照國家最新發佈的《藥品上市許可持有人落實藥品品質安全主體責任監督管理規定》(2022年第126號)及《國家藥監局關於加強藥品上市許可持有人委託生產監督管理工作的公告》(2023年第132號)的要求建立了完善的品質管理系統，具有《檔案管理規程》《員工培訓管理規程》《供應商管理規程》《藥品委託生產管理規程》《藥品上市放行管理規程》《產品銷售管理規程》《用戶投訴處理管理規程》等藥品生產全過程的品質保證制度。本公司具有《糾正與預防措施管理規程》，對產品整個生命週期及管理過程已發現和潛在的不符合進行分析、評估和調查並採取相應的糾正和預防措施，從根本上消除問題產生的原因，防止問題的再次發生，達到改進產品工藝、控制品質風險以及品質體系持續改進的目的。

本公司產品屬於藥品，藥品委託生產品質管理系統通過了藥監局的許可檢查，取得了藥監局頒發的《藥品生產許可證》。

3、 品質培訓

公司對主要品質管理人員進行了多次培訓，培訓涵蓋了品質規範，工藝技術，研發技術，藥物警戒等。2024年，四川思路康瑞藥業有限公司(MAH)作為公司主要生產部門，共計完成培訓15次，其中法規類培訓5次，技術類培訓6次，流程類培訓2次，協議類培訓1次，職責類培訓1次，每次培訓約1小時，涉及468人／次。

The training topics included: **培訓主題如下：**

Training theme **培訓主題**	**Training Category** **培訓類別**	**Training date** **培訓日期**
Drug Commissioning Quality Agreement 藥品委託生產質量協議	Protocols 協議類	2024.02
Guidelines for Quality Risk Management of Pharmaceutical Collinear Manufacturing 《藥品共線生產質量風險管理指南》	Regulation Class 法規類	2024.04
MAH Regulations MAH法規	Regulations Class 法規類	2024.04
Guidelines for contamination control strategies for sterile pharmaceutical products 無菌藥品污染控制策略指南	Regulation Class 法規類	2024.05
1,000L production process and quality standard training 1,000L生產工藝及質量標準培訓	Technical training 技術類	2024.06
Sampling inspection management procedure 抽樣檢驗管理規程	Technical 技術類	2024.06
Key points of supervision for the production process of Envolizumab stock solution (1,000L scale) 恩沃利單抗原液生產工藝（1,000L規模）監管要點	technical 技術類	2024.06
MAH Regulations and regulatory elements of compliance MAH法規及合規監管要素	Regulation Class 法規類	2024.06
Drug traceability Management 藥品追溯管理	Procedure Class 規程類	2024.07
Pharmaceutical excipients, pharmaceutical packaging materials GMP (draft for comment) 藥用輔料、藥用包材GMP（徵求意見稿）	Regulations 法規類	2024.09
2,000L Craft training 2,000L工藝培訓	Technical 技術類	2024.09
2,000L product quality standard and inspection procedure 2,000L產品質量標準及檢驗規程	Technical 技術類	2024.09
Pharmacovigilance Training 藥物警戒培訓	Protocol Classes 規程類	2024.10
Key department and job responsibilities training (production, quality) 關鍵部門及崗位職責培訓（生產、質量）	Responsibilities 職責類	2024.11
Knowledge of microbiological testing 微生物檢驗知識	Technical 技術類	2024.12

Training images:

培訓圖片如下：

4. Customer service

1) Pharmacovigilance and customer complaints

The company attaches great importance to customer rights and services and pays high attention to drug safety work. We actively and comprehensively collect individual safety reports, customer complaints and feedback regarding all our registered/marketed products. We strictly abide by relevant laws and regulations. The company's pharmacovigilance department has specially formulated the following SOPs: "Standard Operating Procedure for the Handling and Submission of Post – marketing Drug Safety Information" (File No.: SLD-SMP-PV-002) and "Standard Operating Procedure for Product Quality Complaints of Marketed Drugs" (File No.: SLD-SMP-PV-029). These are to ensure that the company can handle all adverse reaction reports and quality complaints of products in a timely and compliant manner and implement necessary corrective and preventive measures. Meanwhile, other supporting procedures are also implemented, such as "Standard Operating Procedure for Safety Signal Detection and Management" (File No.: SLD-SMP-PV-004), "Standard Operating Procedure for Hotline Management" (File No.: SLD-SMP-PV-028), "Operating Procedure for Handling Post-marketing Medical Consultations and Queries" (File No.: SLD-SMP-PV-013), "Standard Operating Procedure for Reply Management of Drug Regulatory Inquiries" (File No.: SLD-SMP-PV-012), and "Standard Operating Procedure for the Handling of Feedback Data" (File No.: SLD-SMP-PV-033). As of the end of 2024, a total of 33 customer complaints were received, and all of them have been followed up and resolved.

4、 客戶服務

1) 藥物警戒與客戶投訴

本公司注重客戶權益與服務，高度關注藥物的安全工作，積極全面地收集涉及本公司所有已註冊／已上市產品的個例安全性報告、客戶投訴及回饋。我們嚴格遵守相關法律法規，並通過公司藥物警戒部門專門制定了SOP《藥品上市後安全性信息的處理及遞交標準操作規程》(檔編號：SLD-SMP-PV-002)、《上市藥品產品質量投訴標準操作規程》(檔編號：SLD-SMP-PV-029)，以確保公司及時並合規地處理所有產品的藥品不良反應報告、質量投訴，並實施必要的糾正和預防措施。同時，配套實施的還有《安全性信號檢測與管理標準操作規程》(檔編號：SLD-SMP-PV-004)、《熱線電話的管理標準操作規程》(檔編號：SLD-SMP-PV-028)、《上市後醫學諮詢和質疑處理操作規程》(檔編號：SLD-SMP-PV-013)、《藥監問詢的回覆管理標準操作規程》(檔編號：SLD-SMP-PV-012)、《反饋數據的處理標準操作規程》(檔編號：SLD-SMP-PV-033)等規程。截至2024年底，共接到客戶投訴事件33例，目前均已進行後續追蹤解決。

2) Customer privacy

The company adheres strictly to all relevant national laws and regulations on the protection of personal and organizational data. The safeguarding of customer data permeates every aspect of the company's pharmacovigilance activities. The pharmacovigilance Department has specially formulated the "Standard Operating Procedure for the Safety Management of the Pharmacovigilance Information System" (File No.: SLD-SMP-PV-020),"Standard Operating Procedure for the Management of the Pharmacovigilance Information System" (File No.: SLD-SMP-PV-021) and other SOPs. Across all pharmacovigilance operations, the company applies rigorous confidentiality and security management standards to ensure the privacy and security of customers.

3) Product recall process and handling mechanism

The company has established the *Standard Operating Procedures for Drug Recall* in accordance with the *Drug Recall Management Measures*. The quality management departments of the Marketing Authorization Holder (MAH) and the contracted manufacturer jointly assess drug quality risks. If potential safety hazards are identified, an investigation is immediately initiated. The final decision to recall is made by the MAH's responsible person based on the investigation results.

Recall Process: The recall process begins with assessing potential drug safety hazards. Once a recall is confirmed, a recall plan is developed and initiated. Recall notifications are issued to drug distributors, healthcare facilities, and other relevant entities. Within the specified timeframe, the recall plan, recall notice, and quality/safety risk assessment report must be filed with provincial drug regulatory authorities. Recalled drugs are isolated and stored separately while the recall progress is monitored and reported to provincial authorities. Under supervision from relevant departments, the recalled drugs are disposed of appropriately. The entire process is documented, and after completion, a final report detailing the recall and disposal is submitted to the local provincial drug regulatory department and health administration authority within the required timeframe. If no issues are identified, the recall is formally closed, and all records are archived.

2） 客戶私隱

公司嚴格遵守國家對於個人和單位組織資料保護的相關法律法規，對客戶資料的保護貫穿在公司的藥物警戒各項活動中。藥物警戒部門專門制定了《藥物警戒信息化系統安全管理標準操作規程》(檔編號：SLD-SMP-PV-020)、《藥物警戒信息化系統管理的標準操作規程》(檔編號：SLD-SMP-PV-021)等SOP，在所有藥物警戒活動中公司採取了嚴格的保密和安全管理標準來保護客戶的隱私安全。

3） 產品召回流程及處理機制

公司已按照《藥品召回管理辦法》制定了《藥品召回標準管理規程》，由持有人品質管理部和受託生產企業品質管理部共同確認藥品品質風險，發現藥品存在安全隱患的，立即開展調查，最終由持有人企業負責人根據調查結果決定是否進行召回。

召回的流程：評估藥品安全隱患確定召回後，制定召回計劃，啟動召回，向藥品經營、使用等單位發佈召回通知，在規定的時限內向省級藥監部門備案召回計劃、召回通知、品質安全隱患報告；對召回的藥品隔離存放，同時跟蹤召回進度，並向省級藥監部門報告召回的進展；在相關部門的監督下對召回的藥品進行處理，將召回的全流程進行總結，完成召回後，在規定的時限內將藥品召回和處理情況向所在地省級藥品監督管理部門和衛生健康主管部門報告，均無問題後可關閉召回並歸檔所有資料。

The recall process diagram is as follows:

召回流程圖如下：



- In 2024, the Company has no products that need to be withdrawn or recalled due to health and safety reasons.

- 2024年，公司無因健康與安全原因須撤回和召回的產品。

5. Sustainable supply chain

1) *Supply chain management*

The commercial supply chain of the Company adopts cold chain transportation and supplier management to provide services. We have established a long-term and close cooperative relationship with CR Jiangsu Pharmaceuticl. Through information sharing and management of the supply chain work system with our partners, we manage warehouse management and logistics distribution, and achieve maximum competitiveness of the supply chain at the lowest cost.

Warehouse management: Adopting real time inventory monitoring, safety stock setting, etc., to ensure inventory costs, improve inventory turnover, etc. can meet market demand and avoid resource waste and other problems such as near-expired drugs and dull sale.

Logistics and delivery: We strictly review the transportation equipment and plans of our partners. The partners have complete qualifications and logistics systems, which can ensure that the drugs are safe under the specified temperature and humidity conditions at every stage from storage, transportation to delivery.

At the same time, we also attach great importance to risk management, and comprehensively identify and evaluate various risks that may arise during the operation of the supply chain, including supplier risk, inventory risk, logistics risk, etc. In response to these risks, we have developed corresponding response strategies and plans to reduce the likelihood and impact of risk occurrence, and minimize the losses caused by risks.

2) *Supplier management system*

We abide by the *Government Procurement Law of The People's Republic of China*, the *Law of the People's Republic of China on Bid Invitation and Bidding* and other relevant laws and regulations. Meanwhile, the Company has formulated management documents such as *Procurement Management System*, *Service Provider Evaluation Form* and *New Supplier Information Form* to continuously optimize the supplier management system. The Company adheres to the procurement mode of compliance, transparency and diversification, and actively communicates and cooperates with suppliers. We are establishing a reliable and competitive supply chain guarantee system with our suppliers.

5、 可持續供應鏈

1） *供應鏈管理*

思路迪醫藥商業供應鏈是採用冷鏈運輸和管理供應商提供服務進行的，我們與華潤江蘇建立長期、緊密的合作關係，通過與合作方的供應鏈工作系統資訊共用和管理，針對庫房管理和物流配送進行管理，用最低成本實現了企業的供應鏈的競爭力最大化。

庫房管理：即時庫存監控、安全庫存設定等，保證庫存成本、提高庫存周轉率等，可以滿足市場需求的同時，避免藥品產生近效期、滯銷等問題，造成資源浪費。

物流配送：我們對合作方運輸設備、運輸方案進行嚴格審核，合作方具備完善的資質和完善的物流體系，能確保藥品在儲存、運輸到配送的每一個環節，我們都將確保藥品處於規定的溫度、濕度條件下安全。

同時我們也非常重視風險管理，對供應鏈運行過程中可能出現的各種風險進行全面識別和評估，包括供應商風險、庫存風險、物流風險等。針對這些風險，我們制定相應的應對策略和預案，以降低風險發生的可能和影響，最小化風險導致的損失。

2） *供應商管理系統*

我們恪守《中華人民共和國政府採購法》《中華人民共和國招標投標法》等相關法律法規。同時，公司制定《採購管理制度》《服務商評價表》《供應商新增資訊表》等管理檔，不斷地優化供貨商管理體系。公司秉持合規、透明、多元的採購模式，積極與供貨商進行溝通及合作。我們正在與供貨商建立起一個互相信賴且具有競爭力的供應鏈保障體系。

Prior to the selection of suppliers, we will audit the qualifications of suppliers, fully consider the relevant impact of suppliers on the environment and society, incorporate the audit scoring mechanism, and conduct on-site inspection and audit as appropriate. The suppliers after qualification will be included in our supplier database. We implement annual audit system for suppliers, auditing their product and service quality, brand value, price, communication mechanism, flexibility, and order response speed. We eliminate the suppliers with low scores, so as to ensure the quality of suppliers and reduce the risk of suppliers.

選擇供貨商前，我們會對供貨商的資質進行審核，充分考慮供貨商對環境和社會的相關影響，納入審核評分機制，根據情況會進行實體考察審核，經確認後納入我方供貨商庫。我們對供貨商採用年審制度，對供貨商的產品及服務品質，品牌價值，價格，溝通機制，靈活性，訂單回應速度等審核，根據評分情況，我們會對評分較差的供貨商進行淘汰，以此保證供應商品質，減少供應商風險。

As of the end of the reporting period, the Company has a total of 295 inbound suppliers from multiple regions and countries. The Company has conducted access review and regular verification for each supplier.

截至報告期結束，公司共有入庫供應商295家，來自多個地區和國家。公司對每家供應商均進行了准入審查以及定期核查。

Location 地點		**Number of suppliers** **供應商數量**
Hangzhou	杭州	6
United States	美國	8
Japan	日本	1
Shanghai	上海	171
Beijing	北京	118
Nanjing	南京	4
Guangzhou	廣州	2
Wuxi	無錫	1
Suzhou	蘇州	1
Singapore	新加坡	1
Switzerland	瑞士	1
Shenzhen	深圳	2
Sweden	瑞典	1
Netherlands	荷蘭	1
Kunming	昆明	1
Dongguan	東莞	1
Chengdu	成都	4
Qingdao	青島	7
Xiamen	廈門	1
Shenyang	瀋陽	1
Total	合計	333

IV. PEOPLE FIRST

1. Safeguard employee's rights and interests

Our company strictly adheres to relevant laws and regulations, including the Labor Law of the People's Republic of China and the Labor Contract Law of the People's Republic of China, to effectively protect employee rights and ensure workplace safety. We have established competitive compensation standards and created clear career development pathways to support the growth and well-being of our employees.

1) Employment

Our company adheres to the principles of lawful employment, a people-centric approach, fair competition, and diversified hiring. We have established and continuously improved internal management systems, such as the *Recruitment Management Policy*, to strictly prohibit any recruitment practices involving child labor, forced labor, or any discrimination based on region, gender, or ethnicity. Any violations discovered will be addressed in accordance with company regulations.

The company rigorously follows recruitment procedures and job requirements to ensure compliant hiring practices and to attract high-caliber, capable, and responsible talents.

四、以人為本

1、維護員工權益

思路迪醫藥始終嚴格依循《中華人民共和國勞動法》《中華人民共和國勞動合同法》等一系列法律法規，實實在在地守護員工權益，全力確保工作安全無虞。一方面，精心制定頗具競爭力的薪酬標準；另一方面，着力搭建暢通無阻的職業發展路徑。

1） 員工僱傭

在僱傭原則上，思路迪醫藥堅守合法僱傭、以人為本、公平競爭以及多元化僱傭理念，精心擬定並持續優化如《招聘管理制度》這類內部管理規範。公司堅決杜絕僱傭童工、強制勞工現象，堅決反對在企業招聘環節出現任何地域、性別、民族歧視行為，一旦察覺此類違規行徑，必將嚴格依據規章制度嚴肅處置。

與此同時，公司在人才引進方面，嚴謹遵循既定僱傭流程，全方位、多維度地考察篩選，力求吸納高素質、業務能力出眾且富有責任心的優秀人才，為企業發展注入強勁動力，保障團隊始終保持蓬勃活力與競爭力。

As of the end of 2024, the company has 191 full-time employees. The distribution of full-time employees by gender, age, work location, and educational background is as follows:

截至2024年底，公司全職僱員數191人。全職僱員的性別、年齡、常駐工作地、教育程度分佈如下：

Gender
性別



Age
年齡



Area
區域



Education background
教育程度



Employee turnover rate:

The company's workforce remains relatively stable. In 2024, the overall employee turnover rate was 12%, with the turnover rate for R&D employees at 16%. The distribution of departing employees by gender, age, and work location is as follows:

員工流動率

公司僱員隊伍相對穩定。2024年僱員總體離職率為12%，其中，研發僱員的離職率為16%。離職僱員的性別、年齡、常駐工作地的分佈如下：

Gender
性別



Age
年龄



Area
區域



During the reporting period, there was no voluntary layoff.

報告期內，公司未有主動裁員發生。

2) Employee remuneration and benefits

We are committed to establishing an effective compensation system that aligns remuneration with job value, performance, and individual potential. The company has formulated the *Compensation Management Policy* and *Performance Management Guidelines*, linking remuneration adjustments, bonuses, and promotions to employees' work outcomes.

The company has implemented the *Benefits Management Policy* to standardize and safeguard employee welfare. In addition to statutory benefits, the company provides supplementary benefits, including allowances (transportation, lunch, and communication subsidies), supplemental commercial insurances (medical, accident, etc.), paid sick leaves, annual health check-ups, team-building funds, continuing education incentives, holiday gifts, and condolence payments.

The company complies with statutory working hour regulations and follows the standard two-day weekend. In compliance with national regulations, the company provides statutory holiday leaves with full pay and benefits. Employees are also entitled to annual leaves as stipulated by the *Regulations on Paid Annual Leave for Employees* and *Implementation Measures for Paid Annual Leave for Enterprise Employees*, with full pay and benefits during the leave period. To secure employees' health condition, the company offers 5 days of full-pay sick leave per year. Other types of paid leave include maternity leave, prenatal check-up leave, paternity leave, parental leave, and bereavement leave.

3) Employee promotion

The company is committed to providing employees with fair and equitable opportunities for career development. To standardize job grading and promotion procedures, the company has established the *Employee Promotion Management Policy*. The qualifications for positions are assessed based on multiple dimensions, including work experience, educational background, knowledge and skills, performance results, and comprehensive competencies. Promotions are guided by the principle of emphasizing both integrity and performance.

During the reporting period, 31 employees were promoted to higher positions.

2） 員工薪酬福利

我們致力於打造行之有效的薪酬體系，將薪酬水準與崗位價值、績效、潛力掛鈎。公司出台《員工薪酬管理辦法》及《績效管理規範》，員工薪酬調整、獎金、職位晉升都依據工作成果而定。

公司制定《員工福利管理辦法》保障員工福利落實到位。法定福利之外，補充福利豐富多樣，有交通、午餐、通訊等津貼補助，涵蓋醫療、意外的補充商業保險，帶薪病假、年度體檢、部門團建基金、繼續教育激勵、節日禮品、慰問金等。

公司遵循法定工時制度，實行週末雙休；公司每年根據國家法規，安排法定節假日休假，僱員在國家法定假日休假期間，享受正常薪酬福利待遇；公司僱員依法享有年休假，年休假天數按《職工帶薪年休假條例》和《企業職工帶薪年休假實施辦法》執行，僱員在年休假期間，享受正常薪酬福利待遇；為保障僱員身心健康，公司還為僱員提供了每年5天的全薪病假。其他帶薪假還包括產假、產檢假、陪護假、育兒假、喪假等。

3） 員工晉升

公司堅持為僱員提供公平公正的上升管道及晉升機會。為了規範職位職級和晉升流程，公司制定了《人員晉升管理辦法》。公司的職位任職資格標準包括工作經驗及教育經歷、知識與技能、績效結果、綜合能力等維度。人員晉升遵循德能和業績並重的原則。

報告期內，本公司31人完成了職位晉升，公司並未有裁員發生。

4) Employee training

To standardize training management, the company has established relevant policies, including the *SOP for Employee Training Management* and the *External Training and Examination Management Policy*.

In 2024, 10 employees participated in training programs organized by external institutions, covering topics such as pharmaceutical regulations, quality management, pharmacovigilance, and statistics.

Additionally, all new employees are required to attend new employee orientation training within their first two weeks of employment. The training is organized by the Human Resources Department and delivered by professionals from relevant departments. In 2024, a total of 18 new employees participated in the orientation training.

In 2024, the company conducted a total of 5 company-wide training sessions covering compliance, finance, attendance, performance management, and corporate management policies. The average training duration ranged from 1 to 1.5 hours per session, with an average attendance of over 100 participants. Specifically, male employees completed approximately 240 hours of training, while female employees accounted for around 510 hours of training participation.

2. Employee occupational safety

1) Employee safety management

The company explicitly states in the *Employee Handbook* that employees have the right to a safe and protected working environment. The company believes that ensuring employee health and safety is an integral part of its operations and commits to complying with PRC laws and best practices in health, safety, and environmental matters. Employees are encouraged to immediately report any unsafe working conditions they encounter, become aware of, or observe to their supervisors or relevant departments such as EHS, Human Resources, or Administration. The *Employee Handbook* also emphasizes that employees are responsible not only for their own health and safety but also for that of their colleagues present in the workplace during working hours.

4） 員工培訓

為規範培訓管理，公司制定了《員工培訓管理標準操作規程》及《外部培訓及考試管理辦法》等相應制度。

2024年有10名僱員參加了特定外部機構組織的培訓，內容涉及藥政法規、品質管制、藥物警戒、統計學等。

此外所有新入職的僱員在入職兩周內都會被安排參加新僱員培訓，由人力資源部組織相關部門的專業人員提供培訓。2024年參加新僱員入職培訓的有18人次。

2024年公司共進行了5次全員培訓，涉及合規、財務、考勤、績效、公司管理制度等相關內容。平均培訓時長1 – 1.5小時，平均參會人數超過100人。男性僱員完成培訓時長約240小時，女性完成培訓時長約510小時。

2、 員工職業安全

1） 員工安全管理

公司在《員工手冊》中明確表示，僱員有得到勞動安全和保護的權利。公司認為保證僱員健康和安全是公司經營不可分割的組成部分，公司確保在健康和安全及環保事項上遵守中國法律和良好慣例。公司鼓勵僱員在遇到、得知或注意到其認為可能不安全的工作條件時立即向其主管或相關部門如EHS、人力資源部、行政部門報告，同時《員工手冊》中也明確表示，僱員不僅對自己的健康和安全負有注意義務，還對在工作時間出現在工作場所的其他僱員的健康和安全負有注意義務。

The company has established the *Emergency Response Management Policy* to widely promote awareness of emergency laws, regulations, and common knowledge on prevention and risk avoidance, thereby enhancing employees' emergency awareness and response capabilities. The company actively collaborates with relevant departments to organize emergency training, such as fire drills, for all employees.

公司制定了《應急預案管理制度》，廣泛宣傳應急法律法規和預防、避險等常識，增強僱員應急意識，提高應急處置能力。公司積極配合相關部門，組織全員參加消防演習等應急培訓。

In 2024, the company recorded zero days lost due to work-related injuries and zero fatalities from workplace accidents.

2024年，公司因工傷損失工作日數為0天，因工傷死亡0人。

2) Employee health and safety

2） 員工健康安全

The company strictly adheres to relevant laws and regulations, including the *Occupational Disease Prevention and Control Law of the People's Republic of China*, to provide employees with occupational health protection. To safeguard employee safety and health, the company offers annual health check-ups, provides personal protective equipment, and maintains medical supply kits in the workplace.

公司嚴格遵守《中華人民共和國職業病防治法》等相關法律法規，為僱員提供職業健康保障。公司通過為僱員每年提供健康體檢，提供勞動防護用品、醫療醫藥箱等方式保障僱員安全與健康。

In addition to statutory medical insurance contributions, the company has purchased supplementary commercial medical insurance for employees, covering outpatient care, hospitalization, and accidental injury benefits, to further enhance employee health and well-being.

公司除依法為僱員繳納醫療保險外，還為僱員購買了商業的醫療保險，涵蓋門診、住院、意外傷害等保障內容，以盡力提升員工健康水準。

3. Employee care

3. 員工關愛

The company provides a certain amount of condolence payments to employees who are hospitalized due to illness during their employment or who have lost immediate family member(s). Additionally, the company has established the *Guardian Program*, which offers tumor gene sequencing testing services for employees or their family members diagnosed with cancer, with eligible individuals receiving financial subsidies under the program.

公司對於在職期間因病住院的僱員，直系親屬離世的僱員，發放一定額度的慰問金；公司制定有《守望計劃》，對於罹患腫瘤的僱員或僱員的親屬，購買腫瘤基因測序檢測服務，可根據政策享受費用補貼。

The company also provides support to employees in matters such as Hukou-related formalities and work residence permit applications.

公司為僱員提供包括戶口辦理、工作居住證辦理等支援。

Outstanding employees are recognized and rewarded through various means, including honorary awards, cash bonuses, and equity incentives.

公司對優秀僱員進行表彰和獎勵，包括榮譽獎勵、現金和股權激勵的獎勵。

4. Employee Activities

To enhance employee well-being, strengthen team cohesion, and foster a positive work environment, the company regularly organizes employee activities.

In March 2024, the company held annual conference in Kaiping, Guangdong Province. The event included award ceremonies, summary presentations, employees' performances, team-building exercises, and local sightseeing tours. The awards segment featured a diverse range of categories, recognizing both team and individual achievements.

4. 僱員活動

公司為提升僱員身心健康、增強團隊凝聚力和營造積極向上的工作氛圍，定期組織僱員活動。

2024年3月，公司在廣東省開平市舉辦年會，年會活動包括表彰總結、節目匯演、定向團建、當地旅遊觀光。年會表彰環節設立多元化獎項，包括團隊類獎項和個人類獎項。

In November 2024, the company organized a unique marathon relay race. Employees enthusiastically participated and worked together to complete a total distance of 55.2 kilometers, showcasing their teamwork and spirit.

2024年11月，公司組織僱員舉行了一次別開生面的馬拉松接力跑。僱員踴躍參與，齊心協力，接力跑出了55.2公里的成績。

V. COMMUNITY CONSTRUCTION AND ENGAGEMENT IN PUBLIC WELFARE

Guided by the vision of "being a responsible corporate citizen," 3D Medicines integrates community development into its sustainable growth strategy. Through systematic philanthropic initiatives and cultural embeddedness of social responsibility, we have established a three-dimensional value framework:

Strategic Level: Embedding ESG principles into corporate governance

Operational Level: Implementing diversified philanthropic programs (education empowerment, healthcare accessibility, ecological conservation) with annual donations RMB107.1 million

Cultural Level: Fostering volunteerism through employee engagement programs

五、社區建設，投身公益

公司秉持「以企業公民身份推動社會進步」的核心理念，將社區共建視為可持續發展戰略的重要組成部分。通過系統化公益投入與文化化責任實踐，我們構建了「三位一體」的社會價值體系：

戰略層： 制定ESG（環境、社會、治理）發展框架，將公益事業納入企業戰略決策

執行層： 開展多元化公益項目（教育支持／醫療普惠／生態保護），年度捐贈總額107.1百萬元人民幣

文化層： 建立員工志願服務機制，培養全員社會責任意識

1. Charitable drug donation

Cancer, as a major disease category, imposes tremendous burdens on patients, their families, and society. Mindray Pharmaceutical has always upheld corporate social responsibility, focusing on oncology patient needs, and collaborates with Beijing Kangmeng Foundation to continuously implement patient assistance programs, contributing to cancer prevention and treatment efforts.

In 2024, our program delivered medication assistance, helping patients enhance treatment efficacy, alleviate disease-related pain and economic pressures, reduce societal and family burdens, improve quality of life, and build confidence in fighting the illness. Going forward, we will persistently explore oncology philanthropy, expand assistance scope, and enable more patients to receive substantive support, prolong survival periods, and elevate life quality.

1、 慈善贈藥

癌症作為重大疾病領域，給患者、家庭及社會帶來深重負擔。思路迪醫藥始終秉持企業社會責任，專注腫瘤患者需求，與北京康盟基金會持續合作開展患者援助專案，為腫瘤防治事業貢獻力量。

2024年我們通過該項目提供藥品援助，幫助患者提升治療有效性，緩解疾病痛苦與經濟壓力，減輕社會家庭負擔，改善患者生活品質並樹立抗擊疾病的信心。未來我們將持續深耕腫瘤公益領域，拓展援助範圍，讓更多患者獲得實質幫助，延長生存期間，提高生命質量。

VI. CORPORATE GOVERNANCE

Integrity is the cornerstone of the pharmaceutical industry. Mindray Pharmaceutical strictly adheres to laws and regulations including “The Anti-Unfair Competition Law of the People’s Republic of China” and “Provisional Regulations on Banning Commercial Bribery,” and complies with “The Securities Law of the People’s Republic of China” and HKEX Listing Rules. The company continuously refines its governance framework, implements rigorous risk management and anti-corruption measures, upholds corporate integrity, and ensures long-term sustainable development.

六、企業管治

誠信是醫藥行業的核心基石，思路迪醫藥始終堅持依法經營，嚴格遵守《中華人民共和國反不當競爭法》《禁止商業賄賂行為暫行規定》等法律法規，並在運營中恪守《中華人民共和國證券法》及香港聯交所《上市規則》《上市公司治理準則》。公司持續完善治理體系，深化風險管控與反腐倡廉舉措，維護企業聲譽，為可持續發展提供堅實保障。

1. Corporate Governance system

The board of directors is the core governing body of the company, comprising the chairman, independent directors, and non-independent directors, with independent directors accounting for more than one-third of the board. The board establishes three committees: the Audit Committee, Remuneration Committee, and Nomination Committee, to supervise the management team and ensure the company’s long-term development. The company prioritizes the professional expertise and industry experience of its board members. For the year 2024, the board consists of seven directors, including one executive director, three non-executive directors, and three independent non-executive directors. Among them, three hold doctoral degrees, and one is a female director. All board members possess extensive industry experience and expertise in their respective fields, enabling them to make informed decisions for the company’s comprehensive growth.

1、 治理體系

本公司董事會是公司治理的核心機構，由董事長、獨立董事和非獨立董事構成。其中獨立董事佔董事會的三分之一以上。董事會下設三個委員會：審核委員會、薪酬委員會和提名委員會，以監督公司管理層的行為，保障公司的長期發展。公司高度重視董事會成員的專業背景及行業經驗，2024年度，本公司董事會由7名董事組成，包括1名執行董事，3名非執行董事及3名獨立非執行董事，其中，3位擁有博士學位，1位女性董事。公司董事會成員均具有豐富的行業經驗，以及各自領域的優勢，可以為公司的全面綜合發展做出正確決策。

2. Internal control management

In accordance with the requirements of establishing a modern enterprise system, starting from enterprise risks and combining with its own development situation, the company has established a corporate governance structure and set up organizational structures that meet the company's business scale and operation and management needs. It continuously improves and optimizes the company's internal control management system from five aspects: control environment, risk assessment, control activities, information and communication, and internal supervision to ensure that the internal control system is effective, sound, and has clear responsibilities.

The company attaches great importance to the construction of the internal control management system and has developed a series of company policies and processes, including policies related to company sales, procurement, quality management, pharmacovigilance, legal and compliance, finance, internal audit, human resources, and IT. During the reporting period, to enhance the risk and internal control awareness of management and employees, the company provided publicity and training to employees through online and offline methods.

3. Risk control

The company believes that a sound risk management system is conducive to the company's sustainable development. We attach great importance to the risks in all production and operation links of the company, especially major risk issues related to the company's strategy, major asset purchases and sales, external investments, and related party transactions. The company's risk management system is mainly led by the board of directors and consists of the legal and compliance department, the internal control audit department, and various business departments and business teams. For major risk projects, relevant project initiation meetings will be held, attended by board members, the legal and compliance department, the internal audit department, and relevant business departments. Together, they will identify risk items, consider the potential risks and opportunities of the overall project. After repeated deliberation and review, the final decision will be made by the board of directors.

2、 內控管理

公司按照建立現代企業制度的要求，從企業風險出發，結合自身發展狀況，建立了公司法人治理結構，設立了符合公司業務規模和經營管理需要的組織機構，從控制環境、風險評估、控制活動、資訊與溝通以及內部監督五個方面不斷提升和優化公司的內部控制管理體系，保證內部控制體系有效，健全，職責明確。

公司高度重視內部控制管理體系的搭建，制定了一系列公司政策和流程，包括公司銷售、採購、品質管理、藥物警戒、法律及合規、財務、內部審計、人力資源、IT等有關政策。報告期內，為提升管理層和員工的風險及內控意識，公司通過線上、線下兩種方式為員工提供宣貫培訓。

3、 風險管控

公司認為健全的風險管理體系有利於公司的可持續發展。我們對公司所有生產經營環節的風險予以高度重視，尤其是有關公司戰略，重大資產購買和出售，對外投資，關聯交易的重大風險事項。公司的風險管理體系主要由董事會牽頭，法務與合規部，內控審計部及業務個部門及業務團隊組成。重大風險專案將召開相關立項會議，董事會成員，法務與合規部，內審及相關業務部門共同參加，一同辨別風險事項，考慮整體專案的潛在風險和機會，最終經反覆斟酌覆議後，經董事會最終審批決定。

4. Complaining and whistle-blowing ways

We have issued the "Reporting and Handling Management Measures for Improper Conduct" (procedures for the reporting process) and set up a reporting email address (compliance@3D-medicines.com). We encourage employees to report and file complaints regarding compliance and fraud-related issues to the company, and we do our best to protect the interests and privacy of whistle-blowers to ensure that they are treated fairly and justly. For all reports and complaints, if a preliminary confirmation indicates that an investigation is required, the legal and compliance department will take the lead, jointly establish an employee integrity file with the human resources department, and conduct an investigation after obtaining the authorization of the CEO. The results will be reported to the company's management.

In 2024, the company did not receive any anti-fraud-related reporting information.

4、 投訴舉報途徑

我們出台《不當行為的舉報及處理管理辦法》(舉報程式的規程),設置舉報郵箱(compliance@3D-medicines.com),鼓勵員工對合規及舞弊行為向公司提出舉報與投訴,並最大程度保護舉報人的利益與隱私,以保證舉報人收到公平、公正的對待。對全部舉報及投訴,經初步確認需要調查的,將由法律及合規部部門牽頭,聯合人力資源部門共建員工誠信檔案,經CEO授權後展開調查,向公司管理層彙報並回饋結果。

2024年度,公司未收到任何反舞弊相關的舉報信息。

5. Training on combating corruption and upholding integrity as well as internal control risks

The company organizes new employees to participate in anti-corruption and compliance training every year to enhance their compliance awareness. In 2024, the Human Resources Department organized colleagues from the Legal and Compliance Department to serve as training lecturers, and a total of 4 such training sessions were held.Among them, the promotion of the anti-commercial bribery related systems of 3D Medicines and the training content covered multiple aspects, including the anti-commercial bribery management system, anti-money laundering management system, third-party due diligence investigation management system, management measures for the reporting and handling of improper behaviors, conference and event policies, as well as typical cases in related fields in recent years.All employees of the company actively participated and studied the anti-commercial bribery related systems. By correctly complying with the relevant laws, regulations and systems against commercial bribery, employees can better maintain the company's image and fundamentally promote the upward development of the company.

5、 反貪淨化及內控風險培訓

公司每年組織新入職員工參加反腐,合規培訓,增強員工合規意識。2024年,由人力資源部門組織法律及合規部同事擔任培訓講師,共計舉行此類培訓4場。其中思路迪醫藥反商業賄賂相關制度宣貫、培訓內容涵蓋了多個方面,包括反商業賄賂管理制度、反洗錢管理制度、第三方盡職調查管理制度、不當行為的舉報及處理管理辦法、會議與活動政策以及近年相關領域典型案例等。公司全員積極參與,學習反商業賄賂相關制度,員工正確遵守反商業賄賂相關法規、制度,也能更好地維護公司形象,從根本上促進公司向上發展。

APPENDIX: INDEX TO THE *ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORTING GUIDE* ISSUED BY THE STOCK EXCHANGE OF HONG KONG LIMITED

附錄：香港聯交所《*環境、社會及管治報告指引*》指標索引

Main categories, levels, general disclosures, and KPIs 主要範疇、層面、一般披露及關鍵績效指標		Disclosure section 披露章節
Main Category A. Environment **主要範疇A.環境**		
Level A1: Emissions **層面A1：排放物**		
General disclosure 一般披露	Disclosure about relevant exhaust gas and greenhouse gas emissions, discharges into water and land, hazardous and non-hazardous waste: (a) Policies; and (b) The information about the compliance with relevant laws and regulations that have a significant impact on the issuer. 有關廢氣及溫室氣體排放、向水及土地的排污、有害及無害廢棄物的產生等的： (a) 政策；及 (b) 遵守對發行人有重大影響的相關法律及規例的資料。	Environmental management: Integrated environmental management Coordinate energy conservation and emission reduction Responding to the "Dual Carbon" strategy: Protect green homeland Response to climate change 環境管理： 綜合環境管理 統籌節能減排 回應「雙碳」戰略： 守護綠色家園 應對氣候變化
KPI A1.1 關鍵績效指標A1.1	Emission types and relevant emission data. 排放物種類及相關排放數據。	Integrated environmental management: Pollution discharge management 綜合環境管理： 污染排放管理
KPI A1.2 關鍵績效指標A1.2	Direct (scope 1) and indirect (scope 2) greenhouse gas emissions from energy sources (in tons), and (where appropriate) intensity (e.g. per unit of production volume, per facility). Scope 1 Emissions Scope 2 Emissions 直接（範圍1）及能源間接（範圍2）溫室氣體排放量（以噸計算）及（如適用）密度（如以每產量單位、每項設施計算）。 範圍一排放 範圍二排放	Responding to the "Dual Carbon" strategy: Protect green homeland 回應「雙碳」戰略： 守護綠色家園

Main categories, levels, general disclosures, and KPIs 主要範疇、層面、一般披露及關鍵績效指標		Disclosure section 披露章節
KPI A1.3 關鍵績效指標A1.3	Total hazardous waste produced (in tons) and, where appropriate, intensity (e.g. per unit of production volume, per facility). 所產生有害廢棄物總量（以噸計算）及（如適用）密度（如以每產量單位、每項設施計算）。	Integrated environmental management: Pollution discharge management 綜合環境管理：污染排放管理
KPI A1.4 關鍵績效指標A1.4	Total non-hazardous waste produced (in ton) and, where appropriate, intensity (e.g. per unit of production volume, per facility). 所產生無害廢棄物總量（以噸計算）及（如適用）密度（如以每產量單位、每項設施計算）。	Integrated environmental management: Pollution discharge management 綜合環境管理：污染排放管理
KPI A1.5 關鍵績效指標A1.5	Description of the emission objectives set and the steps taken to achieve such objectives. 描述所訂立的排放量目標及為達到這些目標所採取的步驟。	Integrated environmental management: Pollution discharge management 綜合環境管理：污染排放管理
KPI A1.6 關鍵績效指標A1.6	Description of the method to dispose of hazardous and non-hazardous wastes, waste reduction objectives set and the steps taken to achieve such objectives. 描述處理有害及無害廢棄物的方法，及描述所訂立的減廢目標及為達到這些目標所採取的步驟。	Integrated environmental management: Pollution discharge management 綜合環境管理：污染排放管理
Level A2: Use of Resources **層面A2：資源使用**		
General disclosure 一般披露	Policies on the efficient use of resources, including energy, water and other raw materials. 有效使用資源（包括能源、水及其他原材料）的政策。	Environmental management: Coordinate energy conservation and emission reduction 環境管理：統籌節能減排
KPI A2.1 關鍵績效指標A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (KWh in '000s) and intensity (e.g. per unit of production volume, per facility). 按類型劃分的直接及／或間接能源（如電、氣或油）總耗量（以千個千瓦時計算）及密度（如以每產量單位、每項設施計算）。	Coordinate energy conservation and emission reduction: Energy management 統籌節能減排：能源管理

Main categories, levels, general disclosures, and KPIs 主要範疇、層面、一般披露及關鍵績效指標		Disclosure section 披露章節
KPI A2.2 關鍵績效指標A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per facility). 總耗水量及密度(如以每產量單位、每項設施計算)。	Coordinate energy conservation and emission reduction: Water resources management 統籌節能減排：水資源管理
KPI A2.3 關鍵績效指標A2.3	Description of the energy use efficiency objectives set and the steps taken to achieve such objectives. 描述所訂立的能源使用效益目標及為達到這些目標所採取的步驟。	Coordinate energy conservation and emission reduction: Energy management 統籌節能減排：能源管理
KPI A2.4 關鍵績效指標A2.4	Description of any problems in obtaining the applicable water sources, the water use efficiency objectives set and the steps taken to achieve such objectives. 描述求取適用水源上可有任何問題，以及所訂立的用水效益目標及為達到這些目標所採取的步驟。	Coordinate energy conservation and emission reduction: Water resources management 統籌節能減排：水資源管理
KPI A2.5 關鍵績效指標A2.5	Total packaging material used for finished products (in ton), and, if applicable, proportion of per production unit. 製成品所用包裝材料的總量(以噸計算)及(如適用)每生產單位佔量。	Coordinate energy conservation and emission reduction: Material management 統籌節能減排：材料管理
Level A3: Environment and natural resources **層面A3：環境及天然資源**		
General disclosure 一般披露	Policies on minimizing the issuer's significant impact on the environment and natural resources. 減低發行人對環境及天然資源造成重大影響的政策。	Integrated environmental management: Environmental management system Responding to the "Dual Carbon" strategy: Response to climate change 綜合環境管理：環境管理系統 回應「雙碳」戰略：應對氣候變化

Main categories, levels, general disclosures, and KPIs 主要範疇、層面、一般披露及關鍵績效指標		Disclosure section 披露章節
KPI A3.1 關鍵績效指標A3.1	Description of significant impacts from business activities on the environment and natural resources and the actions taken to manage them. 描述業務活動對環境及天然資源的重大影響及已採取管理有關影響的行動。	Responding to the "Dual Carbon" strategy: Response to climate change 回應「雙碳」戰略：應對氣候變化
Level A4: Climate change **層面A4：氣候變化**		
General disclosure 一般披露	Identification and response to policies prepared for significant climate-related issues that have already had or may have an impact on the issuer. 識別及應對已經及可能會對發行人產生影響的重大氣候相關事宜的政策。	Responding to the "Dual Carbon" strategy: Response to climate change 回應「雙碳」戰略：應對氣候變化
KPI A4.1 關鍵績效指標A4.1	Description of significant climate-related issues that have already had or may have an impact on the issuer and corresponding responsive actions. 描述已經及可能會對發行人產生影響的重大氣候相關事宜，及應對行動。	Responding to the "Dual Carbon" strategy: Response to climate change 回應「雙碳」戰略：應對氣候變化
Main Category B. Society **主要範疇B.社會**		
Employment and Labor Practices **僱傭及勞工常規**		
Level B1: Employment **層面B1：僱傭**		
General disclosure 一般披露	Relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare: (a) Policies; and (b) The information about the compliance with relevant laws and regulations that have a significant impact on the issuer. 有關薪酬及解僱、招聘及晉升、工作時數、假期、平等機會、多元化、反歧視以及其他待遇及福利的： (a) 政策；及 (b) 遵守對發行人有重大影響的相關法律及規例的資料。	People first: Safeguard employee's rights and interests 以人為本：維護員工權益

Main categories, levels, general disclosures, and KPIs 主要範疇、層面、一般披露及關鍵績效指標		Disclosure section 披露章節
KPI B1.1 關鍵績效指標B1.1	Total workforce by gender, employment type (full time or part-time), age group and geographical region. 按性別、僱傭類型(如全職或兼職)、年齡組別及地區劃分的僱員總數。	People first: Employment 以人為本：員工僱傭
KPI B1.2 關鍵績效指標B1.2	Employee turnover rate by gender, age group and geographical region. 按性別、年齡組別及地區劃分的僱員流失比率。	People first: Employment 以人為本：員工僱傭
Level B2: Health and safety 層面B2：健康與安全		
General disclosure 一般披露	Disclosure about providing a safe working environment and protecting employees against occupational hazards: (a) Policies; and (b) The information about the compliance with relevant laws and regulations that have a significant impact on the issuer. 有關提供安全工作環境及保障僱員避免職業性危害的： (a) 政策；及 (b) 遵守對發行人有重大影響的相關法律及規例的資料。	People first: Employee occupational safety 以人為本：員工職業安全
KPI B2.1 關鍵績效指標B2.1	The number and ratio of work-related deaths annually in the past three years (including the reporting year). 過去三年(包括匯報年度)每年因工亡故的人數及比率。	People first: Employee occupational safety 以人為本：員工職業安全
KPI B2.2 關鍵績效指標B2.2	Lost days due to work injury. 因工傷損失工作日數。	People first: Employee occupational safety 以人為本：員工職業安全
KPI B2.3 關鍵績效指標B2.3	Description of occupational health and safety measures adopted, how they are implemented and monitored. Describe training activities. 描述所採納的職業健康與安全措施，以及相關執行及監察方法。	People first: Employee occupational safety 以人為本：員工職業安全

Main categories, levels, general disclosures, and KPIs 主要範疇、層面、一般披露及關鍵績效指標		Disclosure section 披露章節
Level B3: Development and training **層面B3：發展及培訓**		
General disclosure 一般披露	Policies on improving employees' knowledge and skills for discharging duties at work. 有關提升僱員履行工作職責的知識及技能的政策。描述培訓活動。	People first: Employee training 以人為本：員工培訓
KPI B3.1 關鍵績效指標B3.1	The percentage of employees trained by gender and employee category (e.g. senior management, middle management, etc.). 按性別及僱員類別（如高級管理層、中級管理層等）劃分的受訓僱員百分比。	People first: Employee training 以人為本：員工培訓
KPI B3.2 關鍵績效指標B3.2	Average training hours completed per employee by gender and employee category. 按性別及僱員類別劃分，每名僱員完成受訓的平均時數。	People first: Employee training 以人為本：員工培訓
Level B4: Labor standards **層面B4：勞工準則**		
General disclosure 一般披露	Disclosures about preventing child and forced labor: (a) Policies; and (b) The information about the compliance with relevant laws and regulations that have a significant impact on the issuer. 有關防止童工或強制勞工的： (a) 政策；及 (b) 遵守對發行人有重大影響的相關法律及規例的資料。	People first: Employment 以人為本：員工僱傭
KPI B4.1 關鍵績效指標B4.1	Description of measures to review employment practices to avoid child and forced labor. 描述檢討招聘慣例的措施以避免童工及強制勞工。	People first: Employment 以人為本：員工僱傭
KPI B4.2 關鍵績效指標B4.2	Description of steps taken to eliminate such practices when discovered. 描述在發現違規情況時消除有關情況所採取的步驟。	People first: Employment 以人為本：員工僱傭

Main categories, levels, general disclosures, and KPIs 主要範疇、層面、一般披露及關鍵績效指標		Disclosure section 披露章節
Level B5: Supply chain management **層面B5：供應鏈管理**		
General disclosure 一般披露	Environmental and social risk policies for supply chain management. 管理供應鏈的環境及社會風險政策。	Product liability: Supply chain management 產品責任：供應鏈管理
KPI B5.1 關鍵績效指標B5.1	Number of suppliers by geographical region. 按地區劃分的供貨商數目。	Product liability: Supply chain management 產品責任：供應鏈管理
KPI B5.2 關鍵績效指標B5.2	Description of practices relating to engaged suppliers, number of suppliers where the practices are being implemented and how they are implemented and monitored. 描述有關聘用供應商的慣例，向其執行有關慣例的供貨商數目，以及相關執行及監察方法。	Product liability: Supply chain management 產品責任：供應鏈管理
KPI B5.3 關鍵績效指標B5.3	Description of the practices used to identify the environmental and social risks at every stage of the supply chain and relevant implementation and monitoring methods. 描述有關識別供應鏈每個環節的環境及社會風險的慣例，以及相關執行及監察方法。	Product liability: Supply chain management 產品責任：供應鏈管理
KPI B5.4 關鍵績效指標B5.4	Description of the practices used to promote the use of green products and services at the time of selecting suppliers and relevant implementation and monitoring methods. 描述在揀選供應商時促使多用環保產品及服務的慣例，以及相關執行及監察方法。	Product liability: Supply chain management 產品責任：供應鏈管理

Main categories, levels, general disclosures, and KPIs 主要範疇、層面、一般披露及關鍵績效指標		Disclosure section 披露章節
Level B6: Product liability **層面B6：產品責任**		
General disclosure 一般披露	Disclosure about health and safety, advertisement, label and privacy matters relating to products and services provided and methods of redress. (a) Policies; and (b) The information about the compliance with relevant laws and regulations that have a significant impact on the issuer. 有關所提供產品和服務的健康與安全、廣告、標籤及事宜以及私隱補救方法的： (a) 政策；及 (b) 遵守對發行人有重大影響的相關法律及規例的資料。	Product liability: Quality management system Quality control Customer privacy 產品責任： 品質管理系統 品質把控 客戶私隱
KPI B6.1 關鍵績效指標B6.1	Percentage of total products sold or shipped subject to recalls for safety and health reasons. 已售或已運送產品總數中因安全與健康理由而須回收的百分比。	Product liability: Product recall process and handling mechanism 產品責任： 產品召回流程及處理機制
KPI B6.2 關鍵績效指標B6.2	Number of products and services related complaints received and how they are dealt with. 接獲關於產品及服務的投訴數目以及應對方法。	Customer service: Pharmacovigilance and customer complaints 客戶服務： 藥物警戒與客戶投訴
KPI B6.3 關鍵績效指標B6.3	Description of practices relating to safeguarding and protecting intellectual property rights. 描述與維護及保障知識產權有關的慣例。	Innovative R&D: Intellectual property protection 創新研發： 知識產權保護
KPI B6.4 關鍵績效指標B6.4	Description of quality verification process and product recall procedures. 描述質量檢定過程及產品回收程式。	Product liability: Product recall process and handling mechanism 產品責任： 產品召回流程及處理機制
KPI B6.5 關鍵績效指標B6.5	Description of consumer data protection and privacy policies and how they are implemented and monitored. 描述消費者資料保障及私隱政策，以及相關執行及監察方法。	Responsible operation: Customer privacy 責任經營： 客戶私隱

Main categories, levels, general disclosures, and KPIs 主要範疇、層面、一般披露及關鍵績效指標		Disclosure section 披露章節
Level B7: Anti-corruption **層面B7：反貪污**		
General disclosure 一般披露	Disclosure about bribery, extortion, fraud and money laundering: (a) Policies; and (b) Compliance with relevant laws and regulations and other materials that have a significant impact on the issuer. 有關防止賄賂、勒索、欺詐及洗黑錢的： (a) 政策；及 (b) 遵守對發行人有重大影響的相關法律及規例的資料。	Responsible operation: Compliance and anti-fraud management 責任經營： 合規及反舞弊管理
KPI B7.1 關鍵績效指標B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases. 於匯報期內對發行人或其僱員提出並已審結的貪污訴訟案件的數目及訴訟結果。	Responsible operation: Compliance and anti-fraud management 責任經營： 合規及反舞弊管理
KPI B7.2 關鍵績效指標B7.2	Description of preventive measures and whistle-blowing procedures, and how they are implemented and monitored. 描述防範措施及舉報程式，以及相關執行及監察方法。	Responsible operation: Complaining and whistle-blowing ways 責任經營： 投訴舉報途徑
KPI B7.3 關鍵績效指標B7.3	Description of the anti-corruption training provided for the directors and employees. 描述向董事及員工提供的反貪污培訓。	Corporate governance Training on combating corruption and upholding integrity as well as internal control risks 企業管治 反貪淨化及內控風險培訓

Main categories, levels, general disclosures, and KPIs **主要範疇、層面、一般披露及關鍵績效指標**		**Disclosure section** **披露章節**
Level B8: Community investment **層面B8：社區投資**		
General disclosure 一般披露	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its business activities take into consideration the communities' interests. 有關以社區參與來了解營運所在社區需要和確保其業務活動會考慮社區利益的政策。	Community construction and engagement in public welfare 社區建設，投身公益
KPI B8.1 關鍵績效指標B8.1	Focus areas of contribution (e.g. education, environmental concerns, labor needs, health, culture, and sports). 專注貢獻範疇（如教育、環境事宜、勞工需求、健康、文化、體育）。	Community construction and engagement in public welfare 社區建設，投身公益
KPI B8.2 關鍵績效指標B8.2	Resources (e.g. money or time) contributed to the focus areas. 在專注範疇所動用資源（如金錢或時間）。	Community construction and engagement in public welfare 社區建設，投身公益

REFERRAL TABLE

釋義指代表

The Company, we	referred as	3D Medicines Inc., an exempted company with limited liability incorporated under the laws of the Cayman Islands on January 30, 2018, the Shares of which are listed on the Main Board of the Stock Exchange (Stock Code: 1244)
本公司、公司、我們	指	3D Medicines Inc.(思路迪醫藥)及相關附屬公司
恩維達®	referred as	envafolimab (brand name: ENWEIDA, 恩維達®), a subcutaneously injectable PD-L1 inhibitor for the treatment of tumor-agnostic indications
恩維達®	指	恩沃利單抗(品牌名:恩維達®)是一款用於治療泛瘤種的皮下注射PD-L1抑制劑
BLA	referred as	biologic license application
BLA	指	生物製品許可證申請
NDA	referred as	new drug application
NDA	指	新藥申請
MRCT	referred as	multi-regional clinical trial
MRCT	指	多區域臨床試驗
IND	referred as	Investigational New Drug
IND	指	藥臨床試驗申請
PDCA	referred as	Plan – Do – Check – Act
PDCA	指	Plan(計劃)– Do(執行)– Check(檢查)– Act(處理)
PROC	referred as	Platinum-resistant ovarian cancer
PROC	指	鉑類藥物耐藥的卵巢癌
AML	referred as	acute myeloid leukemia, a type of cancer that progresses rapidly and aggressively, and affects the bone marrow and blood
AML	指	急性髓性白血病,一種發病快且侵襲性強的癌症,會影響骨髓和血液
MPM	referred as	Malignant pleural mesothelioma
MPM	指	惡性胸膜間皮瘤
OC	referred as	Ovarian cancer
OC	指	卵巢癌
MM	referred as	Multiple myeloma
MM	指	多發性骨髓瘤
mRNA	referred as	Messenger RNA
mRNA	指	信使核糖核酸
CDE	referred as	Center for Drug Evaluation, National Medical Products Administration
CDE	指	國家藥品監督管理局藥品審評中心

NMPA	referred as	National Medical Products Administration
NMPA	指	國家藥品監督管理局
CSCO	referred as	Chinese Society of Clinical Oncology
CSCO	指	中國臨床腫瘤學會
ESG	referred as	Environmental, Social and Governance
ESG	指	環境，社會與治理
cGMP	referred as	Current Good Manufacturing Practice for Drugs
cGMP	指	動態藥品生產管理規範
ELISA	referred as	Enzyme Linked Immunosorbent Assay
ELISA	指	酶聯免疫吸附測定
FDA	referred as	the United States Food and Drug Administration
FDA	指	美國食品藥品監督管理局
PCR	referred as	Polymerase Chain Reaction
PCR	指	聚合酶鏈反應
XtalPi	referred as	XtalPi
XtalPi	指	晶泰科技
GMP	referred as	Good Manufacturing Practices, the existing guidelines and regulations issued in accordance with the *Drug Administration Law of the People's Republic of China*, as part of quality assurance, are designed to minimize the risks of contamination, cross-contamination, confusion and errors in the manufacture of pharmaceutical products, and ensure that drugs subject to such guidelines and regulations are continuously manufactured and controlled in accordance with the quality and standards applicable to the intended use
GMP	指	藥品生產品質管理規範，根據《中華人民共和國藥品管理法》不時頒佈的指引及規定，作為品質保證的一部分，旨在最大限度地降低藥品生產過程中污染、交叉污染、混淆及差錯等風險，確保受該等指引及規定規限的藥品按照其擬定用途適用的品質及標準持續生產及受控
GCP	referred as	Good Clinical Practice
GCP	指	藥物臨床試驗品質管理規範
SOP	referred as	Standard Operation Procedure
SOP	指	標準作業程序
GDPR	referred as	General Data Protection Regulation
GDPR	指	通用數據保護條例
R&D	referred as	research and development
R&D	指	研究與開發

FORM OF READER'S FEEDBACK

Dear readers:

Hello!

Thanks for reading this report. We are sincerely looking forward to your valuable feedback and advise on the report so that we can continue to improve our work, enhance ESG management ability and upgrade ESG management standard! You may send us the questionnaire through mail or scan the questionnaire and send us a digital version through email. Your active feedback are most welcomed. Thank you!

Mailing Address: 7 Liangshuihe 1st Street, Building 3-6, Yizhuang Biomedical Park, BDA, Beijing, China

Tel.: +86(10)6788 8635
E-mail: fang.xia@3d-medicines.com

讀者意見回饋表

尊敬的讀者：

您好！

感謝您閱讀本報告。我們真誠地期待您對本報告進行評價，提出寶貴意見以便我們持續改進工作，提高ESG管理的能力和水準！您可以通過郵寄或掃描後發送電子郵件將填好的問卷回饋給我們，歡迎積極提出寶貴意見及建議，謝謝！

來函：中國北京市亦莊經濟技術開發區涼水河一街7號，亦莊國際生物醫藥園3區6號樓
電話：+86(10)6788 8635
電郵：fang.xia@3d-medicines.com

1. What kind of stakeholders of the Group do you work for?
   ☐ Shareholder and Investor ☐ Employee ☐ Supplier ☐ Customer
   ☐ Government and Regulator ☐ Community ☐ Partner ☐ Industry Association/NGO
   ☐ Others (Please specify) _____
   您的工作單位屬本集團的哪一類利益相關方？
   ☐ 股東及投資者 ☐ 員工 ☐ 供貨商 ☐ 客戶
   ☐ 政府及監管機構 ☐ 社區 ☐ 合作夥伴 ☐ 行業協會／NGO
   ☐ 其他（請説明）_____

2. Your overall rating of the Report:
   ☐ Good ☐ Fair ☐ Average ☐ Poor
   您對本報告的總體評價如何？
   ☐ 好 ☐ 較好 ☐ 一般 ☐ 差

3. How do you rate the clarity, accuracy and completeness of the information and data disclosed in the Report?
   ☐ Good ☐ Fair ☐ Average ☐ Poor
   您認為本報告所披露的資訊、數據的清晰度、準確性、完整度如何？
   ☐ 好 ☐ 較好 ☐ 一般 ☐ 差

4. How do you rate the comprehensiveness of the economic responsibility undertaken by the Group reflected in the Report?
   ☐ Good ☐ Fair ☐ Average ☐ Poor
   您認為本報告反映本集團所承擔的經濟責任的全面性如何？
   ☐ 好 ☐ 較好 ☐ 一般 ☐ 差

5. How do you rate the comprehensiveness of the environmental responsibility undertaken by the Group reflected in the Report?
   ☐ Good ☐ Fair ☐ Average ☐ Poor
   您認為本報告反映本集團所承擔的環境責任的全面性如何？
   ☐ 好 ☐ 較好 ☐ 一般 ☐ 差

6. How do you rate the comprehensiveness of the social responsibility undertaken by the Group reflected in the Report?
☐ Good ☐ Fair ☐ Average ☐ Poor
您認為本報告反映本集團所承擔的社會責任的全面性如何？
☐ 好 ☐ 較好 ☐ 一般 ☐ 差

7. Do you think the information provided in the Report is readable?
☐ Good ☐ Fair ☐ Average ☐ Poor
您認為本報告請提供的資訊是否具有可讀性？
☐ 好 ☐ 較好 ☐ 一般 ☐ 差

8. What would you like to know that is not disclosed in the Report?
您希望瞭解但並未在本報告中披露的內容有？

_____

9. Your comments and suggestions on the ESG work and report preparation of the Group.
您對本集團環境、社會及企業治理工作和報告編制的意見和建議

_____